---
title: "Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Product information and disease description"
description: "Formulary evidence on Tovecimig (CTX-009, ABL001) in Second-line advanced biliary tract cancer: Product information and disease description. Covers Product description and Place of product in therapy. 242 evidence topics quoted from 71 sources."
canonical: "https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/product-information-and-disease-description"
published: "2026-09-21T22:15:09-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Summary: development and regulatory status as of November 2026

Tovecimig (CTX-009, ABL001, NOV1501, TR009) is investigational and holds no marketing authorization in any jurisdiction. The registrational study in second-line advanced biliary tract cancer is COMPANION-002 (NCT05506943), a randomized, open-label phase 2/3 trial of tovecimig plus paclitaxel versus paclitaxel alone that enrolled 168 participants at 34 sites in the United States and is listed as active, not recruiting, with an estimated primary completion date of 31 August 2027. The trial met its primary endpoint of objective response rate, reported in April 2025 as 17.1% versus 5.3% (p=0.031) and revised in the final analysis to 18.0% versus 5.3% (p=0.0228); median progression-free survival was 4.7 months versus 2.6 months (hazard ratio 0.44, p<0.0001), and the overall survival endpoint was not met.

The FDA granted Fast Track designation to CTX-009 in combination with paclitaxel in April 2024 for previously treated metastatic or locally advanced biliary tract cancer, and orphan drug designation for biliary tract cancer in April 2026. In its report for the second quarter of 2026, filed 6 August 2026, Compass Therapeutics stated that it expected FDA feedback on the COMPANION-002 data during the third quarter of 2026 before a biologics license application filing later in 2026. The July 2026 corporate presentation placed the FDA meeting in the third quarter of 2026, the start of the biologics license application filing in late 2026, and potential approval and launch in 2027, with approval anticipated in the second half of 2027. On 22 September 2026 the company announced that the FDA had recommended a trial demonstrating a survival benefit before a biologics license application submission; the company stated that it does not believe a new trial is warranted and that it continues to prepare a submission while engaging further with the FDA. Its third quarter report of 9 November 2026 repeats that position and states no timing for the submission or for a launch. No submission outside the United States has been announced. The complete COMPANION-002 dataset was published in the Journal of Clinical Oncology and presented at the 2026 European Society for Medical Oncology Congress in October 2026.

Earlier development was conducted in South Korea: a phase 1 monotherapy dose escalation and expansion study (NCT03292783), a phase 1b combination study, and a single-arm phase 2 study of tovecimig plus paclitaxel in biliary tract cancer. Investigator-sponsored trials are ongoing in first-line biliary tract cancer with gemcitabine, cisplatin and durvalumab (NCT06548412), in second-line colorectal cancer with FOLFIRI (NCT07662031), and in second-line glioblastoma with CTX-471 (NCT07392957). A company-sponsored phase 2 basket study in DLL4-positive tumors was planned for initiation in mid-2026.

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm); [Compass Therapeutics regulatory update announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326006162/exh_991.htm); [Compass Therapeutics third quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326007256/exh_991.htm); [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm); [Compass Therapeutics first quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326003005/exh_991.htm); [Compass Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/exh_991.htm); [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm); [Compass Therapeutics Fast Track designation announcement (2024)](https://www.sec.gov/Archives/edgar/data/1738021/000117184324002220/exh_991.htm); [Korea Biomedical Review (2026)](https://www.koreabiomed.com/news/articleView.html?idxno=31224); [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/); [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943); [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Submission planned; BLA in preparation after FDA feedback in September 2026

> “BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE)”
> “today announced that the U.S. Food and Drug Administration (FDA) recommended that Compass conduct a trial demonstrating a survival benefit before proceeding with a Biologics License Application (BLA) submission for tovecimig in patients with previously treated, advanced biliary tract cancer (BTC).”
> “Compass does not believe that a new trial is warranted prior to submitting a BLA based on the data from the Phase 2/3 COMPANION-002 study and the urgent unmet medical need for patients with BTC.”
> “Compass intends to further engage with the FDA as we continue to prepare a BLA submission for tovecimig.”

Source: [Compass Therapeutics regulatory update announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326006162/exh_991.htm)

> “Compass is advancing preparations for a BLA submission for tovecimig in patients with BTC and plans to further engage with the FDA.”
> “BLA submission activities continue as the Company prepares to further engage with the FDA. In September 2026, the Company disclosed that the FDA recommended an additional study demonstrating a survival benefit before submission of a BLA.”

Source: [Compass Therapeutics third quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326007256/exh_991.htm)

<a id="topic-2.1.1-3"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-4"></a>

##### Current development phase: randomized phase 2/3 COMPANION-002 trial

> “Tovecimig (CTX-009), our bispecific antibody targeting DLL4 and VEGF-A, is currently being evaluated in a randomized Phase 2/3 trial in the United States in combination with paclitaxel in patients with biliary tract cancer (“BTC”) who received one prior treatment regimen.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

| Field | Quoted record |
| --- | --- |
| Official title | “A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen” |
| Brief title | “A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)” |
| Lead sponsor | “Compass Therapeutics” |
| Brief summary | “This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.” |
| Estimated primary completion | “2027-08-31” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-2.1.1-5"></a>

##### United States: Fast Track designation

> “today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel for the treatment of patients with metastatic or locally advanced BTC that have been previously treated.”

Source: [Compass Therapeutics Fast Track designation announcement (2024)](https://www.sec.gov/Archives/edgar/data/1738021/000117184324002220/exh_991.htm)

> “This orphan drug designation follows a prior regulatory decision by the FDA to grant fast track designation to tovecimig in April 2024 for the treatment of metastatic or locally advanced biliary tract cancers in the second-line setting.”

Source: [CancerNetwork (2026)](https://www.cancernetwork.com/view/fda-grants-orphan-drug-designation-to-tovecimig-for-biliary-tract-cancer)

<a id="topic-2.1.1-6"></a>

##### United States: orphan drug designation

> “ABL Bio announced Wednesday that Tovecimig (CTX-009/ABL001), an innovative bispecific antibody cancer treatment, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). The drug, currently in development by global partner Compass Therapeutics, targets bile duct cancer.”
> “Upon designation as an orphan drug, the company receives a period of market exclusivity, typically seven years, under U.S. regulations. It is also eligible for benefits such as tax credits, partial waivers of FDA review fees, clinical trial grants, and regulatory support for development.”

Source: [Korea Biomedical Review (2026)](https://www.koreabiomed.com/news/articleView.html?idxno=31224)

> “Tovecimig received Orphan Drug Designation in April and the Company intends to meet with the FDA in advance of its planned BLA submission later this year.”

Source: [Compass Therapeutics first quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326003005/exh_991.htm)

<a id="topic-2.1.1-7"></a>

##### Prior clinical development completed in South Korea

> “Previously, tovecimig underwent a Phase 1 dose escalation and dose expansion monotherapy trial in patients with solid tumors, a Phase 1b trial in combination with chemotherapy, and a Phase 2 trial in combination with chemotherapy in patients with advanced biliary tract cancer, all of which were completed in South Korea.”
> “Based on the efficacy data and following discussions with the FDA, while the trial had met the criteria to advance to Part 2, FDA recommended and we agreed to forego the second stage of the study and advance tovecimig directly to a randomized Phase 2/3 study in patients with BTC treated in the second-line setting.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="topic-2.1.1-8"></a>

##### Planned development beyond second-line biliary tract cancer

> “Beyond BTC, we intend to expand the development of tovecimig to additional solid tumor indications with significant unmet need and a mechanistic rationale for using an angiogenic inhibitor, such as colorectal cancer (“CRC”), ovarian cancer, gastric cancer, renal cell carcinoma, and hepatocellular carcinoma.”
> “We are preparing for a Phase 2 basket study of tovecimig in a broader set of patients with DLL4+ cancers, potentially including gastric, ovarian, renal, hepatocellular, and colorectal cancers. We expect to initiate the study mid-2026 following a comprehensive analysis of the complete data set from the COMPANION-002 BTC trial.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="topic-2.1.1-9"></a>

##### Investigator-sponsored trials in progress

> “The investigator sponsored trial (IST) of tovecimig in combination with the current first-line, standard-of-care regimen of gemcitabine, cisplatin, and durvalumab in patients with BTC (NCT06548412) is ongoing with expansion to additional sites expected.”
> “Additional ISTs of tovecimig have been initiated, including a study of tovecimig plus FOLFIRI in patients with colorectal cancer in the second line setting (NCT07662031); and a novel-novel combination study of tovecimig plus CTX-471 in patients with glioblastoma in the second line setting (NCT07392957).”

Source: [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm)

<a id="topic-2.1.1-10"></a>

##### Presentation of the complete dataset

> “Tovecimig data from this study has also been selected for an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in October.”

Source: [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm)

<a id="topic-2.1.1-11"></a>

##### Peer-reviewed publication and congress presentation of the complete dataset

> “Data from the COMPANION-002 study of tovecimig, including newly disclosed durability of response and crossover-adjusted OS analyses, were published in the Journal of Clinical Oncology and presented at the 2026 ESMO Congress in October.”
> “Full COMPANION-002 data was published in the peer-reviewed Journal of Clinical Oncology and presented at the 2026 European Society for Medical Oncology (ESMO) Congress.”

Source: [Compass Therapeutics third quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326007256/exh_991.htm)

<a id="topic-2.1.1-12"></a>

##### Patent term

> “Patents in these patent families are generally expected to start to expire in 2033, subject to possible extension.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Compass Therapeutics

> “Tovecimig (CTX-009), our bispecific antibody targeting DLL4 and VEGF-A, is currently being evaluated in a randomized Phase 2/3 trial in the United States in combination with paclitaxel in patients with biliary tract cancer (“BTC”) who received one prior treatment regimen.”
> “We have licensed exclusive global rights to tovecimig, outside of South Korea, from ABL Bio, Inc. (“ABL Bio”), a South Korea-based clinical-stage company focused on developing antibody therapeutics. South Korean rights are held by Handok Pharmaceuticals, Inc. (“Handok”) and China rights were out-licensed to Elpiscience Biopharmaceuticals Co., Limited (“Elpiscience”).”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

| Field | Quoted record |
| --- | --- |
| Lead sponsor | “Compass Therapeutics” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-2.1.2.1-2"></a>

###### Nonproprietary name and development codes

> “our Phase 2/3 combination study of tovecimig, which is our new nonproprietary name for CTX-009, in patients with advanced BTC”

Source: [Compass Therapeutics corporate update (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325000116/exh_991.htm)

> “A bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) demonstrates more potent in vitro and in vivo biological activity compared to VEGF or DLL4 targeting monoclonal antibodies alone”

Source: [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/)

> “ABL Bio announced Wednesday that Tovecimig (CTX-009/ABL001), an innovative bispecific antibody cancer treatment, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA).”

Source: [Korea Biomedical Review (2026)](https://www.koreabiomed.com/news/articleView.html?idxno=31224)

<a id="topic-2.1.2.1-3"></a>

###### Brand name

No evidence found.

<a id="topic-2.1.2.1-4"></a>

###### Therapeutic class

> “Our lead product candidate, tovecimig (formerly known as CTX-009), is a bispecific antibody targeting Delta-like ligand 4 (“DLL4”), a ligand of Notch-1, and vascular endothelial growth factor A (“VEGF-A”).”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

> “CTX-009 is a recombinant bispecific antibody that contains two single chain variable fragments (scFv) binding to human DLL4 linked to the C-terminus of heavy chains that bind to human VEGF-A”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.1.2.1-5"></a>

###### Originator: ABL Bio

> “Our wholly owned subsidiary Trigr Therapeutics, Inc. (“TRIGR”) and ABL Bio, a South Korean biotechnology company, entered into an exclusive global (excluding South Korea) license agreement (the “TRIGR License Agreement”) which granted TRIGR a license to ABL001 (renamed CTX-009 and subsequently tovecimig). Under the terms of the agreement, ABL Bio and TRIGR would jointly develop tovecimig, with ABL Bio responsible for development of tovecimig throughout the end of Phase 1 clinical trials and TRIGR responsible for the development of tovecimig from Phase 2 and onward.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

> “Tovecimig is a bispecific antibody developed by ABL Bio and licensed to Compass Therapeutics.”

Source: [Korea Biomedical Review (2026)](https://www.koreabiomed.com/news/articleView.html?idxno=31224)

<a id="topic-2.1.2.1-6"></a>

###### Manufacturing

> “We do not currently own or operate manufacturing facilities for the production of clinical quantities of our product candidates. We have relied on, and intend to continue to rely on, qualified third-party contract manufacturers to produce our product candidates, including clinical supplies to support our clinical trials.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Route of administration and preparation in clinical trials

> “Patients received an intravenous infusion of ABL001/CTX‐009 diluted in 0.9% normal saline (250 mL) over 1 h.”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

| Field | Quoted record |
| --- | --- |
| Intervention type | “Drug” |
| Intervention name | “CTX-009” |
| Intervention description | “IV infusion on day 1 and 14 of every 28 day cycle” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-2.1.2.2-2"></a>

###### Dose units used in clinical trials

> “CTX-009 will be administered at 10 mg/kg on Day 1 and Day 15 of every 28-day cycle.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

> “Nine dose levels were tested in the phase I monotherapy study, at doses ranging from 0.3 to 17.5 mg/kg biweekly.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.1.2.2-3"></a>

###### Commercial formulation, vial strength, and storage

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Average sales price and wholesale acquisition cost of tovecimig

Not applicable.

<a id="topic-2.1.2.3-2"></a>

###### Regulatory and commercial status bearing on the absence of a published price for tovecimig

> “In September 2026, we announced receipt of written communication from the FDA in which they recommended that we conduct a trial to demonstrate a survival benefit prior to submitting a BLA for tovecimig. We do not believe a new trial is warranted prior to submitting a BLA based on the data from the Phase 2/3 COMPANION-002 study and the urgent unmet medical need for patients with BTC. As a result, we intend to further engage with the FDA, as we continue to prepare a BLA submission for tovecimig.”
> “We have incurred significant operating losses since inception and have not generated any revenue from the sale of products and we do not expect to generate any revenue from the sale of products in the near future, if at all.”

Source: [Compass Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326007258/cmpx20260930_10q.htm)

<a id="topic-2.1.2.3-3"></a>

###### Average sales price of paclitaxel, the chemotherapy given with tovecimig in COMPANION-002

> “The drug costs were collected from the Centers for Medicare & Medicaid Services (CMS) and the average sales price (ASP) that the manufacturer reported was adopted”
> “All costs prior to 2022 have been inflated to 2022 US dollars (USD) using the Consumer Price Index”

Source: [Lang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10880349/)

| Model cost input | Baseline value, USD |
| --- | --- |
| Paclitaxel, per 1 mg | “0.115” |
| Administration of intravenous infusion, first hour | “140.16” |
| Administration of intravenous infusion, additional hour | “29.76” |

Source: [Lang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10880349/)

<a id="topic-2.1.2.3-4"></a>

###### Average monthly United States price of orally available kinase inhibitors used in cholangiocarcinoma

> “The cost of drugs was obtained from www.pharmacychecker.com using the FDA label to determine the dosage and number of tablets required per day. This methodology excludes any private or governmental insurance coverage, which would cover the entire cost or more likely a fraction of the stated price.”
> “The average monthly cost for the treatment of neoplastic diseases was $17,900 with a price of $44,000 for futibatinib (used to treat cholangiocarcinomas with FGFR2 fusions) and minimum of $5100 for binimetinib (melanoma).”
> “We retrieved drug prices in November 2023 from www.pharmacychecker.com for the average patient living in the state of North Carolina (ZIP code 28791). These values represent the retail price of a drug at the pharmacy as determined by negotiations between pharmacies and insurers and reflect both wholesale and retail markups.”
> “Results from clinical trials do not favor one drug over the other [83]; the difference in pricing is thus unrelated to clinical efficacy.”
> “Infigratinib had also been approved for the treatment of this uncommon disorder, but the distribution of this FGFR inhibitor has been discontinued in the United States [84].”

Source: [Roskoski (2024)](https://pubmed.ncbi.nlm.nih.gov/38096958/)

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Mechanistic classification

> “ABL001 (NOV1501/TR009), a bispecific antibody targeting VEGF and DLL4, is being developed as an anti-angiogenic cancer therapeutic that strengthens the effects of VEGF inhibitors and eventually overcomes resistance to anti-VEGF therapy”

Source: [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/)

> “Targeting DLL4 expression may be a feasible approach to interfere with angiogenesis, tumorigenesis, and metastasis for anti-cancer effect”

Source: [Kim et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7607148/)

<a id="topic-2.1.2.4-2"></a>

###### AHFS classification or ATC code

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Summary: indication under development

Tovecimig has no approved indication. The indication under development is unresectable advanced, metastatic or recurrent biliary tract cancer, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer and ampullary carcinoma, in adults who have progressed after one prior gemcitabine- and platinum-containing chemotherapy regimen. The FDA Fast Track designation covers CTX-009 in combination with paclitaxel for previously treated metastatic or locally advanced biliary tract cancer, and the April 2026 orphan drug designation covers biliary tract cancer. COMPANION-002 excludes participants who are eligible for an approved molecularly targeted therapy on a labeled regimen after first-line chemotherapy, so the target population is the subgroup without an actionable alteration; the sponsor states that all targeted therapies together are appropriate for approximately 10% to 15% of patients with biliary tract cancer and estimates more than 15,000 patients per year in the United States as potentially eligible. No biomarker selection for DLL4 or VEGF-A expression is required for enrollment in COMPANION-002. Tovecimig is also being studied in first-line biliary tract cancer, colorectal cancer, glioblastoma, and a planned basket study of DLL4-positive tumors.

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943); [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm); [Compass Therapeutics Fast Track designation announcement (2024)](https://www.sec.gov/Archives/edgar/data/1738021/000117184324002220/exh_991.htm); [Korea Biomedical Review (2026)](https://www.koreabiomed.com/news/articleView.html?idxno=31224); [Compass Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/exh_991.htm); [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm)

<a id="topic-2.1.2.5-2"></a>

###### Population studied in COMPANION-002

> “Following conversations with the FDA, we submitted a protocol for a randomized Phase 2/3 trial for tovecimig in combination with paclitaxel in adult patients with unresectable, advanced, metastatic or recurrent biliary tract cancers who have received one prior systemic chemotherapy regimen.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

| Criterion | Quoted record |
| --- | --- |
| Disease | “Histologically or cytologically confirmed unresectable advanced, metastatic, or recurrent biliary tract cancers (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma)” |
| Prior therapy | “Patients must have radiologically documented progression after a prior gemcitabine and platinum containing chemotherapy regimen as first line therapy for locally advanced unresectable or metastatic disease.” |
| Measurable disease | “At least one lesion measurable as defined by RECIST v1.1” |
| Exclusion by alternative therapy | “Patients who are eligible to be treated with a molecularly targeted therapy on a labelled regimen after receiving first-line chemotherapy.” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-2.1.2.5-3"></a>

###### Indication named in the Fast Track designation

> “Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated”

Source: [Compass Therapeutics Fast Track designation announcement (2024)](https://www.sec.gov/Archives/edgar/data/1738021/000117184324002220/exh_991.htm)

<a id="topic-2.1.2.5-4"></a>

###### Size of the population without an actionable alteration

> “The only FDA approved therapies for second line treatment of BTC are targeted therapies that address specific tumor mutations or solid tumors that are microsatellite instability high.”
> “We believe that the combination of all targeted therapies are appropriately 10-15% of patients with BTC.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

> “Over 15K patients/yr potentially eligible for tovecimig”

Source: [Compass Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/exh_991.htm)

<a id="topic-2.1.2.5-5"></a>

###### Other tumor types under study

> “Beyond BTC, we intend to expand the development of tovecimig to additional solid tumor indications with significant unmet need and a mechanistic rationale for using an angiogenic inhibitor, such as colorectal cancer (“CRC”), ovarian cancer, gastric cancer, renal cell carcinoma, and hepatocellular carcinoma.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

| Field | Quoted record |
| --- | --- |
| Official title | “CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers” |
| Lead sponsor | “M.D. Anderson Cancer Center” |

Source: [ClinicalTrials.gov NCT06548412](https://clinicaltrials.gov/study/NCT06548412)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Dual target: DLL4 and VEGF-A

> “Our lead product candidate, tovecimig (formerly known as CTX-009), is a bispecific antibody targeting Delta-like ligand 4 (“DLL4”), a ligand of Notch-1, and vascular endothelial growth factor A (“VEGF-A”). Simultaneous blockade of the VEGF-A and the Notch pathways is known to turn productive angiogenesis into non-productive angiogenesis, which leads to tumor shrinkage and apoptosis.”
> “Tovecimig (formerly known as CTX-009) is an investigational bispecific antibody that is designed to simultaneously block the DLL4 and VEGF-A signaling pathways, which are critical to angiogenesis and tumor vascularization.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="topic-2.1.2.6.1-2"></a>

###### Molecular format: anti-VEGF IgG backbone with C-terminal anti-DLL4 single-chain variable fragments

> “ABL001 is a bispecific antibody that simultaneously targets both DLL4 and VEGF, by linking each C-terminal of an anti-VEGF antibody (bevacizumab-similar) with a DLL4-binding single-chain Fv (scFv)”

Source: [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/)

> “The ABL001 bispecific antibody consists of an anti-VEGF antibody (bevacizumab-like) backbone C-terminally linked with a DLL4-targeting single-chain variable fragment which shows potent binding affinity to VEGF”

Source: [Kim et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7607148/)

> “CTX-009 is a recombinant bispecific antibody that contains two single chain variable fragments (scFv) binding to human DLL4 linked to the C-terminus of heavy chains that bind to human VEGF-A”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.1.2.6.1-3"></a>

###### Rationale for adding DLL4 blockade to VEGF blockade

> “VEGF/VEGFR blockade can inhibit VEGF-driven tumor angiogenesis, and the regression of tumor vessels is dependent on the VEGF signaling pathway. However, VEGF inhibitors alone are not capable of destroying all tumor blood vessels.”
> “Several preclinical xenograft studies have demonstrated that DLL4/Notch blockade inhibited tumor progression by promoting hyperproliferation of endothelial cells, which resulted in an increase in vascular density and a decrease in functional tumor vasculature”

Source: [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/)

> “Hence, given that the VEGF/VEGFR signal transduction pathway and the DLL4/Notch signal transduction pathway affect angiogenesis via different mechanisms of action, CTX-009 was designed to block both pathways in a novel therapeutic format”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.1.2.6.1-4"></a>

###### Target biology in biliary tract cancer

> “VEGF-A overexpression has been reported in BTC, correlating with stage, the presence of metastases and prognosis of the disease”
> “DLL4 is highly expressed in BTC and up-regulation of DLL4 expression is associated with poor survival in patients with BTC”
> “Importantly, DLL4-Notch 1 signaling can be a part of the development of resistance to anti-VEGF therapeutics”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical antitumor activity in gastric and colon cancer xenograft models

> “Both bispecific antibodies, mABL001 and ABL001, inhibited tumor progression in the tested xenograft models at doses ranging from 1 to 6.5 mg/kg”
> “The anti-cancer effects of mABL001 or ABL001 monotherapy were calculated as %TGI ranging from 27.4% to 57.2%, depending on the doses of mABL001 or ABL001 and cancer cell lines in xenograft models”

Source: [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/)

<a id="topic-2.1.2.6.2-2"></a>

###### Effect on tumor vasculature and on target expression in tumor endothelium

> “Based on the results of immunohistochemical analysis of tumor blood vessels, the expression levels of VEGFR-2 and DLL4, dual targets of ABL001, were markedly reduced in tumor endothelial cells after ABL001 treatment compared to that of CD31, a conventional endothelial cell marker.”
> “The combination treatment synergistically inhibited tumor progression compared to each monotherapy. More tumor vessel regression and apoptotic tumor cell induction were observed in tumors treated with the combination therapy, which might be due to tumor vessel normalization.”

Source: [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/)

<a id="topic-2.1.2.6.2-3"></a>

###### Effects on cancer stem cell phenotype, migration, and invasion in gastric cancer models

> “Treatment with human DLL4 therapeutic antibody (anti-hDLL4) or ABL001 slightly reduced GC cell growth in monolayer culture; however, they significantly inhibited cell growth in 3D-culture, suggesting a reduction in the cancer stem cell population. Treatment with anti-hDLL4 or ABL001 also decreased GC cell migration and invasion.”
> “Interestingly, the combination treatment of ABL001 with irinotecan synergistically reduced the GC burden in both xenograft and orthotopic mouse models.”

Source: [Kim et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7607148/)

<a id="topic-2.1.2.6.2-4"></a>

###### Clinical pharmacodynamic or target-engagement biomarkers

No evidence found.

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Population pharmacokinetic model in patients with solid tumors

> “A total of 712 plasma concentrations from 30 patients with relapsed or refractory solid tumors were collected from a phase 1 study”
> “The PK of ABL001/CTX‐009 was well described by a two‐compartment model with a parallel first‐order and Michaelis–Menten elimination kinetics. Body weight was selected as a significant covariate on V1.”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="topic-2.1.2.6.3-2"></a>

###### Model parameter estimates

| Parameter | Estimate (relative standard error, %) |
| --- | --- |
| Clearance, L/h | “0.0184 (18)” |
| Central volume of distribution, L | “3.87 (5)” |
| Intercompartmental clearance, L/h | “0.0207 (16)” |
| Peripheral volume of distribution, L | “1.31 (28)” |

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="topic-2.1.2.6.3-3"></a>

###### Elimination half-life and time to steady state

> “The model‐derived elimination half‐life was approximately 5.7 days, indicating that plasma ABL001/CTX‐009 concentrations would reach a steady‐state in patients with solid tumor in about 4–6 weeks.”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="topic-2.1.2.6.3-4"></a>

###### Simulated exposure: fixed dosing compared with weight-based dosing and alternative intervals

> “Simulations after administrations of fixed or weight‐based doses showed similar plasma concentrations. Additionally, 10 mg/kg for every other week and 15 mg/kg for every three‐week administration showed comparable plasma concentrations.”
> “When comparing the optimal dosing strategy, the ABL001/CTX‐009 plasma concentrations administered every 2 weeks of 10 mg/kg and every 3 weeks of 15 mg/kg showed similar average plasma concentrations”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

| Simulated regimen | Maximal plasma concentration, mg/L | Average plasma concentration at steady state, mg/L |
| --- | --- | --- |
| Fixed dose, 700 mg | “263.1 ± 68.5” | “123.9 ± 65.2” |
| Weight-based dose, 10 mg/kg | “232.3 ± 68.8” | “111.3 ± 66.0” |
| 15 mg/kg every 3 weeks | “296.1 ± 77.4” | “107.6 ± 68.5” |

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="topic-2.1.2.6.3-5"></a>

###### Bioanalytical method

> “Plasma concentrations of ABL001/CTX‐009 were analyzed using a dual antigen‐binding enzyme‐linked immunosorbent assay (ELISA, SpectraMax 190, Molecular Devices). The plasma samples were placed in the ELISA plate coated with recombinant human DLL4, and after the binding process, a horseradish peroxidase‐conjugated human anti‐VEGF A antibody was used to detect the analyte.”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="topic-2.1.2.6.3-6"></a>

###### Immunogenicity and pharmacokinetics in organ impairment

No evidence found.

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### Summary: safety profile observed in clinical development

No prescribing information, boxed warning, contraindication, or risk evaluation and mitigation strategy exists, because tovecimig is investigational. In COMPANION-002, the most common treatment-emergent adverse events in the tovecimig combination arm were hypertension (69%) and fatigue (67%), and the most common related treatment-emergent adverse events of grade 3 or higher were hypertension (44%) and neutropenia (36%). In the single-arm phase 2 study of tovecimig plus paclitaxel in South Korea, all 24 participants had at least one treatment-emergent adverse event and grade 3 or higher events were reported in 95.8%, including decreased neutrophil count in 83.3%, anemia in 20.8%, hypertension in 16.7% and decreased platelet count in 12.5%; grade 3 or higher adverse events of special interest were hemoptysis or hemorrhage in 12.5% and gastrointestinal or tumor perforation in 8.3%, with no pulmonary hypertension, wound healing complication or cardiac failure. In the phase 1 monotherapy dose escalation study of 45 participants, the most frequent treatment-emergent adverse events were hypertension (37.8%), headache (22.2%), asthenia (13.3%), anemia (13.3%) and fatigue (11.1%), no dose-limiting toxicity occurred, and the maximum tolerated dose was not reached at 17.5 mg/kg. In the phase 2 monotherapy study in colorectal cancer, hypertension was the most common treatment-emergent adverse event and occurred only in participants with a prior history of hypertension. An independent data safety monitoring committee reviewed COMPANION-002 safety data at four prespecified meetings and recommended continuation without modification each time. Adverse events reported with other DLL4 and VEGF bispecific antibodies include pulmonary hypertension and gastrointestinal perforation.

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm); [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm); [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/); [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/); [Jimeno et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30229512/); [Gordon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9398147/)

<a id="topic-2.1.2.7.1-2"></a>

###### Prescribing information, boxed warnings, contraindications, and risk evaluation and mitigation strategy

Not applicable.

<a id="topic-2.1.2.7.1-3"></a>

###### COMPANION-002: treatment-emergent adverse events

> “Tovecimig was generally well tolerated and the safety profile was consistent with previously reported data from prior studies, with no new safety signals. The most commonly reported treatment emergent adverse events in the tovecimig combination arm were hypertension (69%) and fatigue (67%). The most common related treatment-emergent adverse events of Grade 3 or higher included hypertension (44%) and neutropenia (36%).”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

> “Safety Monitoring : An independent Data Safety Monitoring Committee reviewed safety data at four separate (pre - specified) meetings and recommended continuation of the study with no modification after each meeting.”

Source: [Compass Therapeutics COMPANION-002 data presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_992.htm)

<a id="topic-2.1.2.7.1-4"></a>

###### Phase 2 in South Korea: grade 3 or higher events and adverse events of special interest

> “Of the 24 patients enrolled in the trial, all patients had at least one treatment emergent adverse event (“TEAE”). Grade 3 or greater TEAEs were reported in 95.8% of patients regardless of the relationship to tovecimig or paclitaxel, including decreased neutrophil count (83.3%), hypertension (16.7%), anemia (20.8%), and decreased platelet count (12.5%). Grade 3 or greater adverse events that were designated to be of special interest (“AESIs”) by the trial investigators were hemoptysis or hemorrhage (12.5%) and GI or tumor perforation (8.3%), with 0% for pulmonary hypertension, wound healing complication and cardiac failure.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

> “The most frequent TEAEs of grade 3 or higher were neutropenia (50.0%), hypertension (16.7%), anemia (12.5%) and thrombocytopenia (8.3%)”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.1.2.7.1-5"></a>

###### Phase 1 monotherapy: dose-limiting toxicity and most frequent adverse events

> “The most frequent treatment emergent adverse events (TEAEs) (>10% of patients) were hypertension (37.8%), headache (22.2%), asthenia (13.3%) anemia (13.3%) and fatigue (11.1%). There were no dose-limiting toxicities observed.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

> “No dose-limiting toxicity (DLT) was observed during the final cohort dose (17.5 mg/kg), and the maximum tolerated dose (MTD) was not reached. The most common treatment-related adverse events (AEs) (including all dose levels and all grades) were hypertension, anemia, anorexia, general weakness, and headache. However, they were well managed for all cohorts.”

Source: [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/)

<a id="topic-2.1.2.7.1-6"></a>

###### Phase 2 monotherapy in colorectal cancer: hypertension

> “Tovecimig’s safety profile was generally consistent with prior studies with hypertension as the most common treatment-emergent adverse event, all of which occurred in patients with a prior history of hypertension.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="topic-2.1.2.7.1-7"></a>

###### Class-related events reported with other DLL4 and VEGF bispecific antibodies

> “The treatment related adverse events (≥15% of patients) were hypertension (57.6%), headache (28.8%), fatigue (25.8%), and pulmonary hypertension (18.2%). Pulmonary hypertension was mostly asymptomatic at doses ≤5 mg/kg (6 Gr1, 1 Gr2), but was more severe at higher doses (4 Gr2, 1 Gr3).”
> “Twelve patients experienced pulmonary hypertension (6 asymptomatic Grade 1, 5 Grade 2 and 1 Grade 3) that was reversible upon drug discontinuation.”
> “Left-sided heart failure was the primary toxicity which limited the therapeutic index of the anti-DLL4 agents. Importantly, no cases of left-sided heart failure were observed in this study of dual DLL4/VEGF inhibition.”
> “There were 19 (28.8%) patients that had navicixizumab withdrawn because of an adverse event. The most common adverse event that resulted in navicixizumab being withdrawn were: pulmonary hypertension (7 [10.6%] patients); hypertension (4 [6.1%] patients); and infusion-related reactions, fatigue, and increased BNP (2 [3.0%] patients each).”
> “Single agent activity has been observed with anti-DLL4 therapy, but treatment duration was limited by cardiotoxicity that is believed to be due to the increased vascular sprouting which occurs when DLL4 is inhibited, but VEGF is not inhibited”

Source: [Jimeno et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30229512/)

> “A TRAE of special interest was gastrointestinal perforation, occurring in 2 patients (3.6%; 1 with ovarian and 1 with prostate cancer) and resulting in 1 death.”

Source: [Gordon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9398147/)

<a id="topic-2.1.2.7.1-8"></a>

###### Hypertension management and cardiac monitoring in the navicixizumab phase 1a study

> “This dose level was expanded to 6 patients; of these, 4 patients discontinued from the study due to hypertension. As a result, a standardized protocol for hypertension management was established (initially using amlodipine or nifedipine at starting doses of 5 and 30 mg daily, when blood pressure was >140/90; ACE inhibitors or beta-blockers were added afterwards as needed) and 6 more patients were treated at 2.5 mg/kg without having to be withdrawn for hypertension.”
> “Patients with ≥ Grade 2 pulmonary hypertension were referred to a cardiologist or pulmonologist to determine what if any further evaluations and/or treatment for their pulmonary hypertension were warranted.”
> “Six patients had a BNP level > 250 pg/mL. Five of these patients had pulmonary hypertension which presumably caused the BNP elevation and 1 patient had a reduction in left ventricular ejection fraction (from 55 to 40%) without pulmonary hypertension.”

Source: [Jimeno et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30229512/)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Eligibility restrictions applied in COMPANION-002

| Criterion | Quoted record |
| --- | --- |
| Minimum age | “18 Years” |
| Performance status | “Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1” |
| Life expectancy | “Predicted life expectancy of at least 12 weeks” |
| Hematologic function | “Hemoglobin ≥ 9.0 g/dL” |
| Hepatic function | “Total bilirubin ≤ 1.5 X ULN” |
| Renal function | “Estimated creatinine clearance ≥ 30 mL/min based on Cockcroft-Gault” |
| Proteinuria | “Urine protein ≤ 1+ by Dipstick” |
| Biliary drainage | “Patients with percutaneous transhepatic biliary drains (PTBD)” |
| Cardiovascular disease | “Uncontrolled arrhythmia” |
| Pulmonary hypertension | “Pulmonary hypertension” |
| Central nervous system metastases | “Symptomatic or uncontrolled central nervous system (CNS) metastasis” |
| Hemorrhage | “Active hemorrhage, hemorrhagic diathesis, coagulopathy or tumor in great arteries” |
| Pulmonary disease | “Interstitial lung disease or pulmonary fibrosis” |
| Paclitaxel tolerance | “Patients with contraindications to paclitaxel therapy” |
| Electrocardiogram | “QT interval (Fridericia's formula) (QTcF) interval > 450msec at the time of screening” |
| Pregnancy and lactation | “Pregnant or lactating patients, or patients planning to become pregnant during the clinical study” |
| Hypersensitivity | “History of hypersensitivity reactions to any components of the investigational product or other drugs of the same class (humanized/human monoclonal antibody drugs) or paclitaxel” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-2.1.2.8-2"></a>

###### Contraception requirements

> “Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile), or be at least 2 years postmenopausal, or commit to use two acceptable forms of birth control (defined as the use of an IUD, a barrier method with spermicide, condoms, or any form of hormonal contraceptives) or abstinence for the duration of the study and for 6 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 6 months following the last dose of study treatment”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.1.2.8-3"></a>

###### Age, sex, and race of participants randomized in COMPANION-002

| Characteristic | Tovecimig plus paclitaxel (n=111) | Paclitaxel (n=57) |
| --- | --- | --- |
| Median age, years | “65.0” | “63.0” |
| Male, n (%) | “53 (47.7)” | “24 (42.1)” |
| Female, n (%) | “58 (52.3)” | “33 (57.9)” |
| Asian, n (%) | “17 (15.3)” | “10 (17.5)” |
| White, n (%) | “84 (75.7)” | “40 (70.2)” |
| African American, n (%) | “4 (3.6)” | “6 (10.5)” |
| Unknown or other, n (%) | “6 (5.4)” | “1 (1.8)” |

Source: [Compass Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/exh_991.htm)

<a id="topic-2.1.2.8-4"></a>

###### Age and organ-function eligibility in the phase 1 study

> “Adult patients (aged ≥19 years) with confirmed of any progressive locally advanced or metastatic solid tumors that had relapsed or were refractory to the standard therapy were enrolled.”
> “Patients who had clinically significant cardiovascular disease, including pulmonary hypertension and myocardial infarction, hypersensitivity to humanized/human mAb, or who previously received anti‐DLL4 antibody were excluded.”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="topic-2.1.2.8-5"></a>

###### Pediatric use, pregnancy and lactation, and dedicated renal or hepatic impairment pharmacokinetic studies

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Tovecimig

<a id="topic-2.1.2.9.1-1"></a>

###### Protocol restrictions on anticoagulants, antiplatelet agents, and prior anticancer therapy

> “Current or recent (within 10 days prior to study treatment) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose will be excluded”
> “Patients with current or recent (within 10 days of study treatment) use of aspirin (>81 mg/day), or other NSAIDs, or other antiplatelets (i.e., dipyridamole, ticlopidine, clopidogrel and cilostazol) will be excluded”
> “Less than 2 weeks have elapsed since patients had chemotherapy or hormone therapy”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.1.2.9.1-2"></a>

###### Covariates tested in the population pharmacokinetic analysis

> “Except for body weight, no other covariate was determined as significant to the PK properties of ABL001/CTX‐009, and the body weight was assessed as a significant covariate for V1 by leading to the largest decrease in the OFV and was added as a covariate on V1 as below:”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="topic-2.1.2.9.1-3"></a>

###### Dedicated clinical drug interaction studies

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Tovecimig on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Preclinical interaction with cytotoxic chemotherapy through tumor vessel normalization

> “Anti-VEGF therapy is known to normalize tumor blood vessels, leading to a more efficient delivery of cytotoxic anti-cancer agents into tumor tissues”
> “Moreover, because the VEGF-binding part of ABL001 is composed of the same IgG backbone and sequence as bevacizumab, ABL001 may have similar activity and function as bevacizumab in tumor vessels, resulting in a more effective delivery of anti-cancer agents, such as paclitaxel or irinotecan.”

Source: [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/)

<a id="topic-2.1.2.9.2-2"></a>

###### Dedicated clinical drug interaction studies

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Summary: doses evaluated and the dose carried into the phase 2/3 trial

The phase 1 first-in-human monotherapy study in South Korea used a 3 plus 3 design across nine dose levels from 0.3 to 17.5 mg/kg given every 2 weeks; no dose-limiting toxicity occurred and the maximum tolerated dose was not reached. The starting dose of 0.3 mg/kg was derived from a no observed adverse effect level of 10 mg/kg in cynomolgus monkeys, converted to a human equivalent dose with a safety factor of 10. All responses in the phase 1 study occurred at dose levels above 10 mg/kg and all confirmed responses at 10 mg/kg or 12.5 mg/kg. The dose taken into the phase 2 study in biliary tract cancer and into COMPANION-002 is 10 mg/kg intravenously on days 1 and 15 of each 28-day cycle, given with paclitaxel 80 mg/m2 on days 1, 8 and 15. Population pharmacokinetic simulations indicate that a fixed dose of 700 mg gives exposure comparable with 10 mg/kg, and that 15 mg/kg every 3 weeks gives an average steady-state concentration comparable with 10 mg/kg every 2 weeks. No labeled dose, dose-modification table, or dosing recommendation for organ impairment exists.

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/); [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/); [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/); [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-2.1.2.10.1-2"></a>

###### COMPANION-002: dose and schedule

> “All patients were dosed with 80 mg/m2 of paclitaxel on days 1, 8 and 15 of every 28-day cycle. Patients in the tovecimig arm were also dosed with 10 mg/kg of tovecimig on days 1 and 15 of each 28-day cycle.”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

> “CTX-009 will be administered at 10 mg/kg on Day 1 and Day 15 of every 28-day cycle. Paclitaxel will be administered 80 mg/m2 on Day 1, Day 8 and Day 15 of every 28-day cycle.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.1.2.10.1-3"></a>

###### Phase 1 dose escalation range and starting dose

> “The study was designed in a classical 3+3 dose-escalation schema where ABL001 is administered by IV across nine dose cohorts ranging from 0.3, 1, 2.5, 5, 7.5, 10, 12.5, 15, to 17.5 mg/kg biweekly”

Source: [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/)

> “The initial dose of 0.3 mg/kg was determined based on the no observed adverse effect level (NOAEL) 10 mg/kg in the monkey model, converted to human equivalent dose with the safety factor of 10.”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="topic-2.1.2.10.1-4"></a>

###### Dose levels at which responses were observed in the phase 1 study

> “All responses were seen at dose levels above 10 mg/kg, and all confirmed responses were seen at the 10 mg/kg or 12.5 mg/kg dose levels”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.1.2.10.1-5"></a>

###### Alternative dosing strategies supported by simulation

> “Based on the simulation results, ABL001/CTX‐009 can be administered as a fixed dose and with a longer dosing interval for follow‐up studies.”
> “Simulation results comparing fixed dosing (700 mg) and weight‐base dosing (10 mg/kg) showed comparable PK properties of ABL001/CTX‐009, supporting the suitability of a non‐weight‐based dosing of ABL001/CTX‐009.”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="topic-2.1.2.10.1-6"></a>

###### Dose modification guidance and dosing in organ impairment

No evidence found.

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Route and schedule

| Field | Quoted record |
| --- | --- |
| Experimental arm | “CTX-009 plus Paclitaxel” |
| CTX-009 administration | “IV infusion on day 1 and 14 of every 28 day cycle” |
| Paclitaxel administration | “IV infusion on day 1, 8, and 15 of every 28 day cycle” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-2.1.2.10.2-2"></a>

###### Infusion preparation and duration in the phase 1 study

> “Patients received an intravenous infusion of ABL001/CTX‐009 diluted in 0.9% normal saline (250 mL) over 1 h. ABL001/CTX‐009 was administered in a 2‐week cycle, with the exception of the second dose, which had a 3‐week interval. Administration continued until unacceptable toxicity or disease progression was identified according to RECIST version 1.1.”

Source: [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)

<a id="topic-2.1.2.10.2-3"></a>

###### Premedication, infusion-rate modification, and preparation instructions for the commercial product

No evidence found.

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Summary: access during development

Tovecimig is available only through clinical trials. COMPANION-002 enrolled 168 participants at 34 sites in the United States, is listed as active, not recruiting, and the registry record states that expanded access is not available. Additional access is through investigator-sponsored trials in first-line biliary tract cancer, colorectal cancer, and glioblastoma. Compass Therapeutics holds exclusive global rights outside South Korea, where rights are held by Handok, and Chinese rights are held by Elpiscience; the company states that it may commercialize independently by building an internal sales and marketing organization or through collaborations. The company reported pre-commercialization expenses beginning in 2026 and describes building a commercial organization to support tovecimig in biliary tract cancer. No distribution model, specialty pharmacy arrangement, site-of-care restriction, or expanded access program has been described.

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943); [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm); [Compass Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/exh_991.htm); [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm)

<a id="topic-2.1.2.11-2"></a>

###### Trial sites and enrollment

> “168 patients across 34 sites in the U.S.”

Source: [Compass Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/exh_991.htm)

<a id="topic-2.1.2.11-3"></a>

###### Commercialization plans and territory rights

> “We hold worldwide rights to all of our product candidates (with the exception of limited countries for tovecimig), which provide us the optionality to grow our internal pipeline independently or partner selected rights to our product candidates in different geographies throughout the world. Subject to receiving marketing approval, we intend to maximize the value of our product candidates by either independently planning to pursue the commercialization of our products in one or more major geographies by building an internal sales and marketing organization, or by seeking collaborations with third parties with commercialization infrastructure.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

> “Building focused commercial organization to support tovecimig in BTC and other future launches”

Source: [Compass Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/exh_991.htm)

> “This was primarily driven by an increase of $1.4 million of pre-commercialization expenses and $0.8 million of higher stock compensation expense.”

Source: [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm)

<a id="topic-2.1.2.11-4"></a>

###### Expanded access program

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Paclitaxel as the mandatory combination partner in the second-line setting

> “CTX-009 will be administered at 10 mg/kg on Day 1 and Day 15 of every 28-day cycle. Paclitaxel will be administered 80 mg/m2 on Day 1, Day 8 and Day 15 of every 28-day cycle.”
> “Paclitaxel was chosen based on the safety and efficacy data from this phase Ib study.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.1.2.12-2"></a>

###### Antihypertensive therapy

> “Uncontrolled hypertension (SBP/DBP >140/90 mmHg) (e.g., patient with SBP/DBP >140/90 mmHg despite the best care including optimizing the anti-hypertensive medication regimen)”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.1.2.12-3"></a>

###### First-line combination with gemcitabine, cisplatin and durvalumab

> “In addition, an investigator sponsored trial of tovecimig in the first-line setting in combination with gemcitabine/cisplatin and durvalumab in patients with BTC was initiated in the first quarter of 2025, led by investigators at The University of Texas MD Anderson Cancer Center.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="topic-2.1.2.12-4"></a>

###### Combination with immune checkpoint inhibitors: preclinical rationale and development plan

> “In this point of view, the results obtained in the current study imply that ABL001 may be another promising partner for combination therapy with immune checkpoint inhibitors, through the facilitation of immune cell infiltration via dual blockade of VEGF and DLL4”

Source: [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/)

> “In addition, we are developing a plan to study the combination of tovecimig with our novel bispecific checkpoint inhibitor, CTX-8371, and with other checkpoint inhibitors.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="topic-2.1.2.12-5"></a>

###### Concomitant medication restrictions

> “Patients expected to require anticancer treatment other than the investigational product during the clinical study”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Tovecimig on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Summary: comparison with available second-line therapy and with other DLL4 and VEGF bispecific antibodies

No systemic therapy is approved by the FDA for second-line biliary tract cancer other than biomarker-directed agents, which the sponsor states are appropriate for approximately 10% to 15% of patients. The regimens most commonly used off-label in this setting are reported to produce objective response rates of about 5% or less and a median overall survival of approximately 6 months; FOLFOX, the regimen tested against best supportive care in a randomized study, produced an objective response rate of 4.9%, a median progression-free survival of 4.0 months and a median overall survival of 6.2 months. In COMPANION-002 the objective response rate with tovecimig plus paclitaxel was 18.0% (20 of 111 participants) compared with 5.3% (3 of 57) with paclitaxel alone (p=0.0228) in the final analysis, and median progression-free survival was 4.7 months compared with 2.6 months (hazard ratio 0.44, p<0.0001). No head-to-head study against another agent has been conducted.

Two other bispecific antibodies targeting DLL4 and VEGF have been tested in first-in-human studies. Navicixizumab (OMP-305B83) was given to 66 participants with refractory solid tumors at 0.5 to 12.5 mg/kg every 3 weeks; the maximum tolerated dose was not reached, 7.5 mg/kg was selected for expansion, treatment-related adverse events in at least 15% of participants were hypertension (57.6%), headache (28.8%), fatigue (25.8%) and pulmonary hypertension (18.2%), the half-life was 11.4 days, anti-drug antibodies formed in 29%, and 4 participants had a partial response. Dilpacimab (ABT-165), a dual-variable domain immunoglobulin, was given to 55 participants at 1.25 to 7.5 mg/kg on days 1 and 15 of 28-day cycles; the most common treatment-related adverse events were hypertension (60.0%), headache (30.9%) and fatigue (21.8%), gastrointestinal perforation occurred in 2 participants (3.6%) with one death, the half-life ranged from 4.9 to 9.5 days, the recommended phase 2 dose was 3.75 mg/kg, and 10.9% of participants had a partial response. Neither agent has reported a randomized trial in biliary tract cancer. Tovecimig differs from both in molecular format, being an anti-VEGF IgG backbone with C-terminal anti-DLL4 single-chain variable fragments, and in dose, at 10 mg/kg every 2 weeks. Pulmonary hypertension, reported in 18.2% of participants receiving navicixizumab, was not reported among grade 3 or higher adverse events of special interest in the phase 2 study of tovecimig plus paclitaxel.

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm); [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm); [Compass Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/exh_991.htm); [Jimeno et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30229512/); [Gordon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9398147/); [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/)

<a id="topic-2.1.2.14-2"></a>

###### Approved therapy in second-line biliary tract cancer

> “The only FDA approved therapies for second line treatment of BTC are targeted therapies that address specific tumor mutations or solid tumors that are microsatellite instability high. For example, in November 2024, Jazz Pharmaceuticals received FDA approval of Ziihera (zanidatamab-hrii) for previously treated, unresectable, or metastatic human epidermal growth factor receptor (“HER2”) positive (IHC 3+) biliary tract cancer, which may be beneficial to the small subset of patients in whom HER2 is amplified overexpressed.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

> “For the vast majority of patients with BTC whose tumors do not harbor an actionable mutation with an approved targeted therapy, there is currently no FDA-approved treatment in the second line setting. The therapeutics most commonly used in this setting, which are not labeled or approved by the FDA for the treatment of patients with BTC, generally have an ORR of ~5% or less and patients face a median OS of approximately six months.”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-2.1.2.14-3"></a>

###### FOLFOX as the historical second-line benchmark

> “For reference, one regimen that has been studied in patients with advanced BTC is the three-drug combination FOLFOX. FOLFOX demonstrated an ORR of 4.9%, a median PFS of 4.0 months, and a median OS of 6.2 months in a randomized study against best supportive care.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

> “2L treatment options are ineffective – FOLFOX in this setting has a 5% ORR and a median OS of 6.1 months”

Source: [Compass Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/exh_991.htm)

<a id="topic-2.1.2.14-4"></a>

###### Navicixizumab (OMP-305B83): first-in-human results

> “Navicixizumab (OMP-305B83) is a bispecific antibody that inhibits delta-like ligand 4 and vascular endothelial growth factor.”
> “Sixty-six patients were treated once every 3 weeks in 8 dose-escalation cohorts (0.5, 1, 2.5, 3.5, 5, 7.5, 10, and 12.5 mg/kg) and an expansion cohort (7.5 mg/kg).”
> “Navicixizumab's half-life was 11.4 days and there was a moderate (29%) incidence of anti-drug antibody formation. Four patients (3 ovarian cancer, 1 uterine carcinosarcoma) had a partial response and 17 patients had stable disease.”

Source: [Jimeno et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30229512/)

<a id="topic-2.1.2.14-5"></a>

###### Navicixizumab (OMP-305B83): dose escalation outcome and recommended phase 2 dose

> “Cohorts of 6 patients were then enrolled at 5, 7.5 and 10 mg/kg without any DLTs. Enrollment at 12.5 mg/kg dose level was concluded after 5 patients, because of chronic toxicity (pulmonary hypertension) that emerged outside of the DLT window.”
> “The maximum tolerated dose (MTD) for navicixizumab was not determined based on protocol-defined criteria. A dose of 7.5 mg/kg once every 3 weeks was chosen for the expansion cohort based on chronic toxicity that was observed at higher dose levels. However, as 3 patients receiving 7.5 mg/kg developed Grade 2 pulmonary hypertension and the maximal efficacy was observed at 3.5 mg/kg, the recommended Phase 2 dose is 5 mg/kg Q3W.”

Source: [Jimeno et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30229512/)

<a id="topic-2.1.2.14-6"></a>

###### Dilpacimab (ABT-165): first-in-human results

> “Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.”
> “Eligible patients (≥18 years) received dilpacimab intravenously on days 1 and 15 in 28-day cycles at escalating dose levels (range, 1.25–7.5 mg/kg) until progressive disease or unacceptable toxicity.”
> “The PK of dilpacimab showed a half-life ranging from 4.9 to 9.5 days, and biomarker analysis demonstrated that the drug bound to both VEGF and DLL4 targets. The recommended phase II dose for dilpacimab monotherapy was established as 3.75 mg/kg, primarily on the basis of tolerability through multiple cycles. A partial response was achieved in 10.9% of patients (including 4 of 16 patients with ovarian cancer).”

Source: [Gordon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9398147/)

<a id="topic-2.1.2.14-7"></a>

###### Relationship to bevacizumab and ramucirumab

> “Other approved anti-angiogenic antibody therapeutics including bevacizumab, an antagonist of the VEGF ligand (VEGF-A: Avastin ® ), and ramucirumab, an antagonist of the VEGF receptor (VEGFR-2: Cyramza ® ), are generally used in a combination regimen with chemotherapy to treat cancer patients, providing more efficacious therapeutic options for cancer patients”

Source: [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/)

<a id="topic-2.1.2.14-8"></a>

###### COMPANION-002: final objective response rate and progression-free survival

> “In the final data analysis, the overall response rate (ORR), the primary endpoint in the study, improved to 18.0% (20/111 patients) in the tovecimig combination arm from a previously reported 17.1%.”

Source: [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm)

> “Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of median progression-free survival (PFS) of 4.7 months versus 2.6 months, providing a 56% reduction in the risk of progression (hazard ratio=0.44, p<0.0001).”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-2.1.2.14-9"></a>

###### Head-to-head or indirect treatment comparisons

No evidence found.

Additional sources: [ASCO Daily News (2026)](https://dailynews.ascopubs.org/do/tovecimig-ctx-009-bispecific-antibody-targeting-dll4-and-vegf-a-perspectives-field)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Summary: definition of biliary tract cancer and of the second-line advanced setting

Biliary tract cancer is an adenocarcinoma arising from the epithelium of the biliary tree and comprises intrahepatic cholangiocarcinoma, extrahepatic (perihilar and distal) cholangiocarcinoma, gallbladder cancer, and carcinoma of the ampulla of Vater. Cholangiocarcinoma is subdivided anatomically: intrahepatic cholangiocarcinoma arises above the second-order bile ducts, and the insertion of the cystic duct separates perihilar from distal cholangiocarcinoma. In the United States, perihilar disease accounts for approximately 50% to 60% of cholangiocarcinomas, distal disease for 20% to 30%, and intrahepatic disease for 10% to 20%. Biliary tract cancers account for less than 1% of all cancers worldwide.

Second-line advanced biliary tract cancer is the disease state of participants with locally advanced or metastatic biliary tract cancer whose disease has progressed after first-line systemic therapy, historically cisplatin and gemcitabine and now cisplatin, gemcitabine, and an anti-PD-L1 or anti-PD-1 antibody. In the ABC-06 randomized trial, the primary tumour sites among 162 participants enrolled after progression on cisplatin and gemcitabine were intrahepatic cholangiocarcinoma (72 of 162, 44%), extrahepatic cholangiocarcinoma (45, 28%), gallbladder (34, 21%), and ampullary cancer (11, 7%).

Most risk factors share chronic inflammation of the biliary epithelium and bile stasis. Reported associations include choledochal cyst, Caroli disease, primary sclerosing cholangitis, choledocholithiasis and cholelithiasis, cirrhosis, chronic hepatitis B and C, inflammatory bowel disease, chronic pancreatitis, type 2 diabetes, non-alcoholic fatty liver disease, and, in endemic regions of Southeast Asia, infection with the liver flukes Opisthorchis viverrini and Clonorchis sinensis. In most countries the majority of cases remain sporadic with no identifiable risk factor.

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/); [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/); [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.1.1-2"></a>

###### Definition: biliary tract cancer comprises cholangiocarcinoma, gallbladder cancer, and ampullary cancer

> “Biliary tract cancer is a term that includes cholangiocarcinoma (either intrahepatic or extrahepatic in origin) and cancers of the gallbladder and ampulla of Vater. These uncommon cancers arising from the biliary tract account for less than 1% of all cancers worldwide.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

> “Biliary tract cancer (BTC), including cholangiocarcinoma, gallbladder cancer, and (to a lesser degree) ampullary tumours, are aggressive malignancies.”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.1.1-3"></a>

###### Definition: anatomical classification of cholangiocarcinoma

> “Cholangiocarcinoma (CCA) constitutes a diverse group of malignancies emerging in the biliary tree. CCAs are divided into three subtypes depending on their anatomical site of origin: intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) CCA”
> “iCCAs arise above the second-order bile ducts, whereas the point of anatomical distinction between pCCA and dCCA is the insertion of the cystic duct.”
> “In the USA, pCCA is the single largest group, accounting for approximately 50–60% of all CCAs, followed by dCCA (20–30%) and iCCA (10–20%)”
> “CCA is the second most common primary hepatic malignancy after hepatocellular carcinoma (HCC), comprising approximately 15% of all primary liver tumours and 3% of gastrointestinal cancers”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

> “Cholangiocarcinoma (CCA) is a highly lethal, epithelial cell malignancy that occurs anywhere along the biliary tree and/or within the hepatic parenchyma.”
> “These cancers are heterogeneous and are best classified according to the primary, anatomic subtype as intrahepatic CCA (iCCA), perihilar CCA (pCCA) or distal CCA (dCCA)”
> “Most CCAs are adenocarcinomas and other histological subtypes, such as adenosquamous carcinoma or clear cell carcinoma, are encountered rarely”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.1-4"></a>

###### Definition: guideline classification of biliary tract cancer and its subtypes

> “BTCs refer to a spectrum of invasive tumours, usually adenocarcinomas, arising from the gallbladder or cystic duct [gallbladder carcinoma (GBC)] or the biliary tree (CCA).”
> “pCCA and dCCA collectively comprise extrahepatic CCA, although this latter classification is discouraged due to insufficient anatomical specificity.”

Source: [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/)

<a id="topic-2.2.1.1-5"></a>

###### Definition: the second-line population after first-line cisplatin and gemcitabine

> “Patients were eligible if they were aged 18 years or older and had histologically or cytologically verified locally advanced or metastatic biliary tract cancer (including cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma) with documented radiological disease progression to previous first-line cisplatin and gemcitabine chemotherapy.”
> “In all enrolled patients, the primary tumour sites were intrahepatic cholangiocarcinoma (in 72 [44%] of 162 patients), extrahepatic cholangiocarcinoma (45 [28%]), gallbladder (34 [21%]), and ampullary cancer (11 [7%]).”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

> “More recently, the addition of immune checkpoint inhibitors [specifically durvalumab (TOPAZ-1 trial3) and pembrolizumab (KEYNOTE-966 trial4)] to cisplatin–gemcitabine has demonstrated significant improvements in overall survival (OS).”
> “However, for ∼60% of patients diagnosed with ABC, there is currently no targetable alteration identified; thus second-line therapy options will be limited to further cytotoxic chemotherapy.”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.1.1-6"></a>

###### Etiology: chronic inflammation of the biliary epithelium and bile stasis

> “Several risk factors, both common and rare, have been linked to CCA (Table 1). Although some risk factors are shared by all forms of CCA, others seem to be more specific for one subtype and seem to be more important in different regions. A common characteristic amongst many of these risk factors is that they are associated with chronic inflammation of the biliary epithelium and bile stasis”
> “However, in most locations, the majority of CCA cases remain sporadic, without any identifiable risk factor present.”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

> “In endemic regions, liver fluke infection is associated with CCA, owing to the oncogenic effect of the associated chronic biliary tract inflammation. In other regions, CCA can be associated with chronic biliary tract inflammation owing to choledocholithiasis, cholelithiasis, or primary sclerosing cholangitis, but most CCAs have no identifiable cause.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.1-7"></a>

###### Etiology: reported effect sizes for risk factors for cholangiocarcinoma

| Risk factor | Study type | Reported effect size, intrahepatic disease | Reported effect size, extrahepatic disease |
| --- | --- | --- | --- |
| Caroli disease | “Population-based study” | “OR 38 for iCCA” | “OR 97 for eCCA” |
| Choledochal cyst | “Meta-analysis” | “OR 26.71 for iCCA” | “OR 34.94 for eCCA” |
| Primary sclerosing cholangitis | “Population-based study” | “OR 22 for iCCA” | “OR 41 for eCCA” |
| Cirrhosis | “Meta-analysis” | “OR 15.32 for iCCA” | “OR 3.82 for eCCA” |
| Choledocholithiasis | “Meta-analysis” | “OR 10.08 for iCCA” | “OR 18.58 for eCCA” |
| Chronic hepatitis B | “Meta-analysis” | “OR 4.57 for iCCA” | “OR 2.11 for eCCA” |
| Chronic hepatitis C | “Meta-analysis” | “OR 4.28 for iCCA” | “OR 1.98 for eCCA” |
| Cholelithiasis | “Meta-analysis” | “OR 3.38 for iCCA” | “OR 5.92 for eCCA” |
| Chronic pancreatitis | “Population-based study” | “OR 2.7 for iCCA” | “OR 6.6 for eCCA” |
| Inflammatory bowel disease | “Meta-analysis” | “OR 2.68 for iCCA” | “OR 2.37 for eCCA” |
| Nonalcoholic fatty liver disease | “Meta-analysis” | “OR 2.2 for iCCA” | “OR 1.5 for eCCA” |
| Type 2 diabetes mellitus | “Meta-analysis” | “OR 1.73 for iCCA” | “OR 1.5 for eCCA” |

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

<a id="topic-2.2.1.1-8"></a>

###### Etiology: liver fluke infection in endemic regions

> “Infections with specific trematodes are a major cause of CCA in some regions, and these flatworm parasites are group 1 biological carcinogens, that is, definite causes of cancer, including several fish-borne liver flukes of the Opisthorchiidae family”
> “The incidence of CCA associated with liver fluke infection, calculated as an age-standardized rate, varies by geographical region and other risk factors but has exceeded 100 per 100,000 in men and 40 per 100,000 in women in hotspots in northeast Thailand”
> “At least 700 million people are at risk of infection with these liver flukes”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.1-9"></a>

###### Etiology: subtype-specific risk factors outside endemic regions

> “In Western countries, primary sclerosing cholangitis is the most well-known risk factor for CCA7. Several risk factors are associated with all three subtypes, whereas others are subtype-specific. For example, Caroli disease and choledochal cysts (congenital disorders of the bile ducts) have a strong association with all three CCA subtypes52,53. By contrast, cirrhosis, non-alcoholic fatty liver disease (NAFLD) and hepatitis B have a stronger association with iCCA, whereas choledocholithiasis (bile duct stones) has a stronger correlation with pCCA and/or dCCA52. The global rise in obesity and NAFLD may be contributing to the rising rates of iCCA. Although multiple risk factors for CCA exist, most CCAs do not have an identifiable risk factor.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.1-10"></a>

###### Etiology: regional variation in risk factors and reported odds ratios

> “Risk factors for CCA, which vary between regions, share chronic inflammation of the biliary epithelium as a key feature.”
> “Cirrhosis and hepatotropic viruses are risk factors for iCCA, with odds ratios of 22.92 [95% confidence interval (CI) 18.24-28.79] for cirrhosis, 5.10 (95% CI 2.91-8.95) for hepatitis B virus (HBV) and 4.84 (95% CI 2.41-9.71) for hepatitis C virus (HCV), according to a recent meta-analysis.”

Source: [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Second-line advanced biliary tract cancer

<a id="topic-2.2.1.2.1-1"></a>

###### Summary: incidence of biliary tract cancer and of the second-line population

No registry reports the incidence of second-line advanced biliary tract cancer directly; it is estimated from the incidence of biliary tract cancer and the proportion of participants who reach a second line of therapy. For 2026, the American Cancer Society estimates 42,340 new cases of liver and intrahepatic bile duct cancer and 12,640 new cases of gallbladder and other biliary cancer in the United States. Compass Therapeutics estimates approximately 26,500 people newly diagnosed with biliary tract cancer in the United States each year and over 200,000 worldwide.

In the Surveillance, Epidemiology, and End Results program, the overall age-adjusted incidence of cholangiocarcinoma from 2001 to 2017 was 3.65 per 100 000 person-years and rose 43.8% over that period, driven by a 148.8% rise in intrahepatic cholangiocarcinoma against a 7.5% rise in extrahepatic cholangiocarcinoma. In North American Association of Central Cancer Registries data for 1999 to 2013, intrahepatic and extrahepatic cholangiocarcinoma rates increased by 3.2% and 1.8% per year while gallbladder cancer rates declined among women and among people aged 45 years or older. Globally, GLOBOCAN 2024 estimated 126,384 new gallbladder cancers and 843,045 new cancers of the liver and intrahepatic bile duct.

Only a subset of the incident population reaches second-line treatment. ABC-06 reported that 15% to 25% of participants receive second-line therapy, and a United States commercial-claims cohort of 413 participants with advanced biliary tract cancer found that 46% initiated a second line and 16.5% a third line.

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/); [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm); [Javle et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526482/); [Van Dyke et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6467796/); [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/); [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.2.1-2"></a>

###### Incidence: estimated new United States cases and deaths in 2026

| Cancer site | Estimated new cases, both sexes | Estimated deaths, both sexes |
| --- | --- | --- |
| Liver and intrahepatic bile duct | “42,340” | “30,980” |
| Gallbladder and other biliary | “12,640” | “4590” |
| All sites | “2,114,850” | “626,140” |

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

<a id="topic-2.2.1.2.1-3"></a>

###### Incidence: manufacturer estimate of newly diagnosed biliary tract cancer

> “We estimate that there are approximately 26,500 patients newly diagnosed with BTC in the United States each year and over 200,000 patients worldwide.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="topic-2.2.1.2.1-4"></a>

###### Incidence: SEER rates for liver and intrahepatic bile duct cancer

> “The rate of new cases of liver and intrahepatic bile duct cancer was 9.5 per 100,000 men and women per year.”
> “Liver and intrahepatic bile duct cancer is most frequently diagnosed among people aged 65–74.”

Source: [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html)

<a id="topic-2.2.1.2.1-5"></a>

###### Incidence: cholangiocarcinoma incidence and trends in the United States, 2001 to 2017

> “From 2001-2017, CCA, iCCA, and eCCA incidence (per 100 000 person-years) increased 43.8% (3.08 to 4.43), 148.8% (0.80 to 1.99), and 7.5% (2.28 to 2.45), respectively.”
> “CCA incidence increased with age, with greatest increase among younger patients (18-44 years, 81.0%).”
> “The overall age-adjusted incidence of CCA from 2001 to 2017 was 3.65 per 100 000 p-y (iCCA, 1.19; eCCA, 2.46).”
> “The overall age-adjusted incidence of CCA from 2001 to 2017 increased with patient’s age (18-44 years, 0.27; 45-64 years, 3.10; 65-84 years, 14.19; ≥85 years, 22.05)”
> “The overall incidence of CCA from 2001 to 2017 was 4.40 in men vs 3.08 in women”

Source: [Javle et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526482/)

<a id="topic-2.2.1.2.1-6"></a>

###### Incidence: trends by anatomic site in the United States, 1999 to 2013

> “We characterized demographic differences in biliary tract cancer incidence rates and time trends by anatomic site. We used population-based North American Association of Central Cancer Registries data to calculate age-adjusted incidence rates, incidence rate ratios (IRRs), and estimated annual percent change per year (eAPC) for 1999–2013 by site and demographic group.”
> “During this period, ICC (eAPC=3.2%/year, P<0.0001) and ECC (1.8%/year, P=0.001) rates steadily increased across sex and racial/ethnic groups.”
> “While GBC rates increased among 18–44-year-olds (eAPC=1.8%/year, P=0.01), they decreased among people ≥45 years (−0.4 %/year, P=0.009).”

Source: [Van Dyke et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6467796/)

<a id="topic-2.2.1.2.1-7"></a>

###### Incidence: global estimates for 2024

| Cancer site | Estimated new cases worldwide, 2024 | Percentage of all cases | Estimated deaths worldwide, 2024 |
| --- | --- | --- | --- |
| Liver and intrahepatic bile duct | “843,045” | “4.1” | “732,489” |
| Gallbladder | “126,384” | “0.6” | “92,029” |

Source: [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)

<a id="topic-2.2.1.2.1-8"></a>

###### Incidence: proportion of participants who reach second-line therapy

> “Patients with advanced biliary tract cancer often experience a rapid decline in performance status following progression on first-line chemotherapy, and only 15–25% receive second-line therapy.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

> “Of 413 patients, 84.5% received gemcitabine-based first-line (1L) treatment, 46% received second-line treatment, and 16.5% received third-line (3L) treatment.”
> “In total, 46% (n = 190) of patients initiated second line of therapy (2LOT), which predominantly involved 5-fluorouracil (5FU)-based mono- or combination chemotherapy”

Source: [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Second-line advanced biliary tract cancer

<a id="topic-2.2.1.2.2-1"></a>

###### Summary: prevalence of biliary tract cancer and the size of the second-line pool

Prevalence of biliary tract cancer is low relative to incidence because survival is short. SEER estimated 116,514 people living with liver and intrahepatic bile duct cancer in the United States in 2023, and the lifetime risk of a diagnosis of liver and intrahepatic bile duct cancer is approximately 1.1 percent. A SEER analysis of 40,030 cholangiocarcinoma cases reported a 16-year limited-duration prevalence for cholangiocarcinoma of 5.92, higher for extrahepatic (4.23) than intrahepatic (1.69) disease, with the intrahepatic figure rising across successive periods from 0.60 in 2001 to 2006 to 1.37 in 2013 to 2017.

The prevalent second-line population is smaller still, because median overall survival from second-line randomization was 6.2 months with FOLFOX and 5.3 months with active symptom control alone in ABC-06. Approximately 60% of participants with advanced biliary tract cancer have no targetable alteration and are therefore candidates for non-targeted second-line therapy; the manufacturer places the share with targeted mutations at approximately 15% to 20%.

Source: [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html); [Javle et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526482/); [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/); [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="topic-2.2.1.2.2-2"></a>

###### Prevalence: people living with liver and intrahepatic bile duct cancer in the United States

> “In 2023, there were an estimated 116,514 people living with liver and intrahepatic bile duct cancer in the United States.”
> “Approximately 1.1 percent of men and women will be diagnosed with liver and intrahepatic bile duct cancer at some point during their lifetime, based on 2021–2023 data.”

Source: [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html)

<a id="topic-2.2.1.2.2-3"></a>

###### Prevalence: limited-duration prevalence of cholangiocarcinoma in SEER, 2001 to 2017

> “From 2001 to 2017, the LDP of CCA was 5.92% (Table 3) and was higher for eCCA vs iCCA (4.23% vs 1.69%). The LDP of iCCA increased from 2001-2006 (0.60%) to 2007-2012 (0.98%) to 2013-2017 (1.37%), whereas the LDP for eCCA remained relatively stable.”
> “LDP is defined as the number of people alive on a certain day who had a diagnosis of the disease within the past 16 years; as of January 1, 2017.”

Source: [Javle et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526482/)

<a id="topic-2.2.1.2.2-4"></a>

###### Prevalence: share of the advanced population without a targetable alteration

> “However, for ∼60% of patients diagnosed with ABC, there is currently no targetable alteration identified; thus second-line therapy options will be limited to further cytotoxic chemotherapy.”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

> “Patients with BTC have a poor prognosis despite first-line treatment with chemotherapy and immunotherapy, and there is no generally accepted standard of care in later lines of treatment, except for therapies addressing targeted mutations, which is estimated to be approximately 15% to 20% of the patient population.”

Source: [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Summary: survival across the disease course and in the second-line setting

Biliary tract cancer is usually detected late and is rarely curable. SEER records 21.9% five-year relative survival for liver and intrahepatic bile duct cancer overall, falling to 13.4% for regional and 3.6% for distant disease. Across 40,030 SEER cholangiocarcinoma cases diagnosed from 2001 to 2017, median overall survival from diagnosis was 8 months overall, 6 months for intrahepatic and 9 months for extrahepatic disease.

In the first-line advanced setting, the TOPAZ-1 three-year update reported median overall survival of 12.9 months with durvalumab plus gemcitabine and cisplatin versus 11.3 months with placebo plus chemotherapy, and 36-month overall survival of 14.6% versus 6.9%. KEYNOTE-966 reported median overall survival of 12.7 months with pembrolizumab plus gemcitabine and cisplatin versus 10.9 months with chemotherapy alone.

After progression on first-line therapy, survival is measured in months. In ABC-06, median overall survival was 6.2 months with active symptom control plus FOLFOX versus 5.3 months with active symptom control alone (adjusted hazard ratio 0.69, 95% CI 0.50 to 0.97, p=0.031), with 12-month survival of 25.9% and 11.4%. Median progression-free survival with FOLFOX was 4.0 months. Baseline tumour marker elevation stratifies this population sharply: median overall survival fell from 8.9 months when none of CA19-9, CEA, and CA125 was elevated to 3.2 months when all three were. In a United States claims cohort of 413 participants receiving systemic therapy for advanced biliary tract cancer, median overall survival was 11.5 months from index and 13.3 months from first presumed diagnosis, and all-cause mortality was 53%.

Source: [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html); [Javle et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526482/); [Oh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40381735/); [Kelley et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37075781/); [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/); [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.3-2"></a>

###### Natural history: asymptomatic early disease and late presentation

> “CCAs are usually asymptomatic in early stages and, therefore, often diagnosed when the disease is already in advanced stages, which highly compromises therapeutic options, resulting in a dismal prognosis”
> “Despite advances in CCA awareness, knowledge, diagnosis and therapies, patient prognosis has not improved substantially in the past decade, with 5-year survival (7–20%) and tumour recurrence rates after resection still disappointing”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

> “The prognosis is poor, with an all-stage 5-year overall survival of less than 20%.”
> “Patients are rarely diagnosed with early-stage disease and therefore curative surgery and adjuvant therapy is only feasible for a small proportion of patients.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

<a id="topic-2.2.1.3-3"></a>

###### Survival: SEER stage distribution and five-year relative survival, liver and intrahepatic bile duct cancer

| Stage at diagnosis | Percent of cases | 5-year relative survival |
| --- | --- | --- |
| Localized | “45%” | “37.4%” |
| Regional | “23%” | “13.4%” |
| Distant | “21%” | “3.6%” |
| Unknown | “10%” | “11.6%” |

Source: [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html)

> “For liver and intrahepatic bile duct cancer, 44.7% are diagnosed at the local stage. The 5-year relative survival for localized liver and intrahepatic bile duct cancer is 37.4%.”

Source: [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html)

<a id="topic-2.2.1.3-4"></a>

###### Survival: median overall survival by cholangiocarcinoma subtype in SEER

> “Median overall survival from diagnosis was 8, 6, 9, and 2 months for CCA, iCCA, eCCA, and CUP.”
> “The annual mortality rate declined from 45.2% in 2001 to 38.7% in 2016 for CCA, and from 57.1% in 2001 to 41.2% in 2016 for iCCA, but the rates for iCCA remained consistently higher than for eCCA, which generally remained stable (40.9% in 2001 vs 37.0% in 2016; Fig. 2F).”

Source: [Javle et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526482/)

<a id="topic-2.2.1.3-5"></a>

###### Survival: first-line overall survival with durvalumab plus chemotherapy, TOPAZ-1 three-year update

> “After a median 41.3 (95% CI 39.3-44.1) months' follow-up in all participants, median OS (95% CI) for durvalumab+GemCis vs. placebo+GemCis was 12.9 (11.6-14.1) vs. 11.3 (10.1-12.5) months (hazard ratio, 0.74 [95% CI 0.63-0.87]); 36-month OS rate was 14.6% vs. 6.9%, respectively.”
> “The 36-month Kaplan-Meier OS rate for the durvalumab arm was more than double that of the placebo arm, and the OS rate ratio for durvalumab vs. placebo increased over time (12 months: 1.15; 24 months: 1.75; 36 months: 2.12).”
> “In total, 88/685 (12.8%) participants were eLTS, with more eLTS in the durvalumab arm (58/341 [17.0%]) vs. the placebo arm (30/344 [8.7%]).”

Source: [Oh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40381735/)

<a id="topic-2.2.1.3-6"></a>

###### Survival: first-line overall survival with pembrolizumab plus chemotherapy, KEYNOTE-966

> “Median overall survival was 12·7 months (95% CI 11·5-13·6) in the pembrolizumab group versus 10·9 months (9·9-11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72-0·95]; one-sided p=0·0034 [significance threshold, p=0·0200]).”

Source: [Kelley et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37075781/)

<a id="topic-2.2.1.3-7"></a>

###### Survival: second-line overall survival in ABC-06

> “Median overall survival was 6·2 months (95% CI 5·4–7·6) in the ASC plus FOLFOX group versus 5·3 months (4·1–5·8) in the ASC alone group (adjusted HR 0·69 [95% CI 0·50–0·97], p=0·031; figure 2).”
> “The overall survival rate in the ASC alone group was 35·5% (95% CI 25·2–46·0) at 6 months and 11·4% (5·6–19·5) at 12 months, compared with 50·6% (39·3–60·9) at 6 months and 25·9% (17·0–35·8) at 12 months in the ASC plus FOLFOX group.”
> “Median progression-free survival was 4·0 months (95% CI 3·2–5·0; appendix p 4).”
> “The progression-free survival rate was 66·7% (95% CI 55·3–75·8) at 3 months, 32·1% (22·3–42·3) at 6 months, and 8·6% (3·8–16·0) at 12 months.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

<a id="topic-2.2.1.3-8"></a>

###### Survival: prognostic value of baseline tumour markers in the second-line setting

> “Baseline CA19-9 data were available for 135 of 162 patients: 92 (68.1%) high, 43 (31.9%) low. High baseline CA19-9 was associated with shorter unadjusted OS [4.4 versus 6.4 months; hazard ratio (HR) 1.97, 95% confidence interval (CI) 1.33-2.93, P < 0.001] and unadjusted PFS (3.2 versus 5.0 months; HR 1.53, 95% CI 1.05-2.23, P = 0.027) in the FOLFOX arm.”
> “With each additional tumour marker that was elevated at baseline, median OS was numerically shorter: unadjusted median OS was 8.9 months if all tumour markers at baseline were not elevated and 7.0 months, 4.0 months, and 3.2 months in the event of having 1, 2, or 3 elevated baseline tumour markers, respectively (Figure 1).”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.1.3-9"></a>

###### Survival: real-world United States outcomes across lines of therapy

> “All-cause mortality was 53% with a median survival of 11.5 months.”
> “The median OS from the index date was 11.5 months (Figure 3A & B). In total, 70.1% (n = 289), 47.8% (n = 197), 34.9% (n = 144) and 29.6% (n = 122) of patients survived 6, 12, 18 and 24 months, respectively, from the index date.”
> “The median OS time from first presumed BTC diagnosis was 13.3 months.”
> “The median time on 2LOT was 3.6 months and was longer for patients with stage III disease (4.6 months) than for patients with stage IV and stage I/II disease (3.6 months).”

Source: [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.3-10"></a>

###### Mortality: United States and global mortality burden

> “Liver and intrahepatic bile duct cancer is the sixth leading cause of cancer death in the United States. The death rate was 6.6 per 100,000 men and women per year based on 2020–2024 deaths, age-adjusted.”

Source: [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html)

<a id="topic-2.2.1.3-11"></a>

###### Mortality: gallbladder cancer survival has not improved over three decades

> “Among the 55 studies included, more than 320,000 people, suggest that survival improvements for gallbladder cancer have stagnated over the past three decades. No significant improvements in 5-year relative survival rates were observed worldwide. After age standardization, the highest 5-year relative survival rate is 30.6 % (Changzhou, China, 2011–2013 and Korea, 2013–2019), while the lowest is 6.0 % (Austria, 1990).”

Source: [Xiao et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11894304/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Summary: cholangiocarcinogenesis, molecular subtypes, and angiogenic signalling

Biliary tract cancers arise from cholangiocytes and related biliary epithelium, and can also develop from peribiliary glands and hepatocytes depending on the underlying liver disease and location. Chronic inflammation and bile stasis drive cholangiocarcinogenesis through pro-inflammatory cytokines, growth factors, and bile acids in the tumour microenvironment. The tumours are highly desmoplastic, with a reactive stroma of cancer-associated fibroblasts that secrete paracrine factors promoting proliferation, chemotaxis, and angiogenesis, including VEGF-A and VEGF-C.

Genomic alterations track with anatomic subtype. FGFR2 fusions and IDH1 and IDH2 mutations occur almost exclusively in intrahepatic disease, while PRKACA and PRKACB fusions and ELF3 mutations characterize extrahepatic tumours. In a real-world comprehensive genomic profiling series of 91 biliary tract tumours, the most frequently altered genes were TP53 (51 of 91, 56.0%), KRAS (21 of 91, 23.1%), CDKN2A (18 of 91, 19.8%), SMAD4 (14 of 91, 15.4%), and ARID1A or PBRM1 (12 of 91, 13.2%).

Angiogenesis is a relevant pathway for the disease and for the mechanism of tovecimig. Transcriptomic stratification of cholangiocarcinoma identified VEGF signalling among the main oncogenic networks in participants with poor overall survival. In intrahepatic cholangiocarcinoma, NOTCH1, HES1, MMP13, DLL4, and VEGFA were significantly upregulated in tumours compared with adjacent non-tumorous tissue, and selective NOTCH1 inhibition downregulated VEGFA, HES1, and MMP13 and inhibited vessel formation in an in vitro angiogenesis model.

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/); [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/); [Nakaoka et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13406710/); [Mancarella et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7370218/)

<a id="topic-2.2.1.4-2"></a>

###### Pathophysiology: cell of origin and desmoplastic tumour immune microenvironment

> “CCA displays features of cholangiocyte differentiation and probably arises predominantly from the epithelial cells lining the bile ducts, which are termed cholangiocytes; however, the cancers may also develop from peribiliary glands and hepatocytes, depending on the underlying liver disease and location”
> “These cancers are highly desmoplastic and are enmeshed in dense networks of inflammatory cells and matrix termed the tumour immune microenvironment”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

> “CCA tumours, and particularly iCCAs and pCCAs, are characterized by a reactive desmoplastic stroma containing cancer-associated fibroblasts (CAFs) that crosstalk with CCA cells secreting paracrine factors such as heparin-binding EGF-like growth factor, stromal-cell derived factor 1 (SDF1), platelet-derived growth factor (PDGF)-B and extracellular matrix (ECM) proteins”
> “CAFs secrete a multitude of signalling molecules (such as IL-1β, PDGF-B, heparin-binding EGF-like growth factor and SDF1) that promote cancer progression by enhancing proliferation, survival, chemotaxis and angiogenesis”
> “Following stimulation by PDGF-D originated from the tumoural cholangiocytes in vitro, CAFs secrete VEGF-A and VEGF-C, which recruit and assemble lymphatic endothelial cells in vascular structures susceptible to tumour cell intravasation”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

<a id="topic-2.2.1.4-3"></a>

###### Pathophysiology: cholangiocarcinogenesis driven by inflammatory and growth factor signalling

> “Cholangiocarcinogenesis is orchestrated by a complex interplay of extracellular ligands (such as pro-inflammatory cytokines, growth factors and bile acids, among others), which are present in the tumour microenvironment (TME), and increased expression and/or aberrant activation of cell surface receptors and the deregulation of intracellular signalling pathways, finally leading to cell proliferation, survival and genetic and/or epigenetic alterations”
> “The most common genes that might be mutated or amplified resulting in the overactivation of some of these pathways are KRAS, BRAF, ARID1, PBRM1, BAP1, IDH1 and IDH2.”
> “The main oncogenic networks comprised WNT-CTNNB1, MYC, ERBB, TNF and VEGF signalling, emphasizing cell survival signalling pathways in patients with poor OS”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

<a id="topic-2.2.1.4-4"></a>

###### Pathophysiology: genomic alterations differ by anatomic subtype

> “Among CCAs, genetic aberrations differ depending on their anatomic locations; for example, FGFR2 fusions are almost exclusively found in iCCAs, whereas PRKCA–PRKCB fusions are observed in pCCAs and dCCAs”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

> “Small bile duct iCCA can be characterized by isocitrate dehydrogenase (IDH1, IDH2) mutations or fibroblast growth factor receptor 2 (FGFR2) fusions”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

<a id="topic-2.2.1.4-5"></a>

###### Pathophysiology: frequency of recurrent alterations in a real-world profiling series

> “The most frequently altered genes were TP53 (51/91, 56.0%), KRAS (21/91, 23.1%), CDKN2A (18/91, 19.8%), SMAD4 (14/91, 15.4%), and ARID1A/PBRM1 (12/91, 13.2%).”

Source: [Nakaoka et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13406710/)

<a id="topic-2.2.1.4-6"></a>

###### Pathophysiology: DLL4, VEGFA, and Notch-dependent angiogenesis in intrahepatic cholangiocarcinoma

> “Finally, RNA-sequencing expression data of iCCA patients and matched surrounding normal liver tissues downloaded from the GEO database demonstrated that NOTCH1, HES1, MMP13, DLL4, and VEGFA genes were significantly upregulated in tumors compared with adjacent nontumorous tissues.”
> “Furthermore, gene expression analysis of iCCA mouse tissues treated with LY3039478 revealed a downregulation of VEGFA, HES1, and MMP13 genes.”
> “In the same tissues, DLL4 and CD31 co-localized, and their expression was significantly inhibited in the treated mice, as it happened in the case of MMP13.”
> “In an in vitro angiogenesis model, LY3039478 inhibited vessel formation, which was restored by the addition of MMP13.”
> “Thus, the present data provide new knowledge on Notch signaling in iCCA, and support the inhibition of the Notch cascade as a promising strategy for the treatment of this disease.”

Source: [Mancarella et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7370218/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Summary: diagnostic pathway and molecular profiling

Diagnosis rests on cross-sectional imaging followed by tissue confirmation, with the route to tissue determined by anatomic subtype. Contrast-enhanced CT and MRI are the reference imaging modalities; magnetic resonance cholangiopancreatography is used for perihilar and distal disease and endoscopic retrograde cholangiography provides biliary brushings for cytology and fluorescence in situ hybridization. Biliary cytology has low sensitivity for perihilar disease (43% in one meta-analysis) and FISH is more sensitive (65% versus 19% in one series). CA19-9 is the principal serum biomarker but lacks specificity. Histopathological or cytological confirmation is mandatory because no radiological pattern is specific for cholangiocarcinoma.

For the second-line setting, molecular profiling determines whether a targeted option exists. The Pan-Asian adapted ESMO guideline recommends a core biopsy for diagnostic pathology and molecular profiling before any non-surgical treatment and molecular analysis in advanced disease considered suitable for systemic treatment, and recommends ivosidenib for IDH1 mutations, FGFR inhibitors for FGFR2 fusions, pembrolizumab for MSI-H or dMMR tumours, and dabrafenib with trametinib for BRAF V600E tumours after at least one prior line. In a real-world series of 91 biliary tract tumours, comprehensive genomic profiling identified potentially actionable alterations in 21 participants (23.1%), yielded expert panel therapeutic options in 15 (16.5%), and led to genomically matched therapy in 7 (7.7%).

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/); [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/); [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/); [Nakaoka et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13406710/)

<a id="topic-2.2.1.5-2"></a>

###### Diagnosis: guideline recommendations on pathology, molecular biology, and staging

> “Molecular analysis is recommended in advanced disease considered suitable for systemic treatment [I, A]”
> “Elevated CA 19-9 is associated with poorer prognosis and can be useful for assessing response to treatment [III, C]”
> “Thoraco-abdomino-pelvic CT remains the reference examination for lymph node and metastatic extension [III, A]”
> “FDG-PET is not recommended for imaging of the primary tumour. However, it may be considered where there is clinical suspicion of nodal metastases, distant metastases and disease recurrence [III, C; consensus = 100%].”
> “Radiological imaging should be carried out before ERCP or PTC in patients with jaundice [III, A]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.1.5-3"></a>

###### Diagnosis: guideline recommendations on tissue acquisition for molecular profiling

> “A core biopsy should be obtained for diagnostic pathology and molecular profiling before any nonsurgical treatment [III, A].”
> “In patients with d/pCCA without extraductal metastasis, PTC- or ERCP-guided biopsies should be carried out to obtain adequate tissue for diagnostic pathology and molecular profiling [III, A].”

Source: [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/)

<a id="topic-2.2.1.5-4"></a>

###### Diagnosis: composition of the molecular testing panel

> “Parallel sequencing of several genes using focused next-generation sequencing (NGS) is preferred over single gene testing.”
> “Currently, the gene panel should include the respective coding DNA regions (target regions) of isocitrate dehydrogenase 1 (IDH1), human epidermal growth factor receptor 2 (HER2)/neu [v-erb-b2 avian erythroblastic leukaemia viral oncogene homologue 2 (ERBB2)] and BRAF to test for hotspot mutations, but the rapidly evolving landscape of drug targets and predictive biomarkers may soon necessitate larger panels.”

Source: [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/)

<a id="topic-2.2.1.5-5"></a>

###### Diagnosis: guideline recommendations on second-line molecularly directed therapy

> “Ivosidenib is recommended for the treatment of patients with CCA and IDH1 mutations who have progressed after ≥1 prior line of systemic therapy”
> “FGFR inhibitors are recommended for the treatment of patients with FGFR2 fusions who have progressed after ≥1 prior line of systemic therapy”
> “Pembrolizumab is recommended in patients with MSI-H/dMMR who have progressed on or are intolerant to prior non-immune checkpoint inhibitor-containing treatment”
> “Dabrafenib-trametinib is recommended for the treatment of patients with BRAFV600E mutations who have progressed after ≥1 prior line of systemic therapy”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.1.5-6"></a>

###### Diagnosis: imaging and tissue acquisition in intrahepatic cholangiocarcinoma

> “iCCA is often seen at presentation as an intrahepatic mass and is incidentally found in 25–30% of patients”
> “Carbohydrate antigen 19-9 (CA19-9) is the primary serum biomarker used in CCA diagnosis, although it has subpar specificity and can be elevated in various conditions, such as biliary obstruction or pancreatic cancer.”
> “MRI may provide enhanced assessment of the primary mass, whereas CT imaging has superior detection of vascular enhancement and is, therefore, important in determining resectability”
> “Histopathological analysis of a biopsy specimen remains the mainstay for confirmation of an iCCA diagnosis.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.5-7"></a>

###### Diagnosis: perihilar and distal cholangiocarcinoma

> “Patients with pCCA and dCCA typically present with painless jaundice owing to underlying biliary obstruction.”
> “The sensitivity and specificity of MRCP to distinguish benign and malignant causes of hilar obstruction are 87% and 85%, respectively”
> “ERC has a diagnostic and therapeutic role in pCCA and dCCA as it enables detection of malignant strictures and acquisition of biliary brushings for cytology and fluorescence in situ hybridization (FISH) analysis.”
> “However, the sensitivity of biliary cytology for pCCA detection is low (43% according to one meta-analysis127). FISH analysis has a higher sensitivity than cytology (65% versus 19% in one series) and similar specificity for detection of CCA”
> “EUS–FNA has a higher sensitivity for detection of dCCA than detection of pCCA (81% versus 59%)”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.5-8"></a>

###### Diagnosis: histological confirmation and the limits of imaging

> “As no specific CCA radiology pattern exists, histopathological or cytological analysis is mandatory to confirm the diagnosis1,28. This diagnosis is based on the WHO classification of biliary tract cancer showing an adenocarcinoma or mucinous carcinoma101, with tubular and/or papillary structures and a variable fibrous stroma102.”
> “CT is considered the standard imaging method for the preoperative assessment of both iCCA and pCCA; it provides a comprehensive evaluation of the primary tumour, the relationship with adjacent structures, and potential thoracic and abdominal spread”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

<a id="topic-2.2.1.5-9"></a>

###### Diagnosis: staging and its limitations

> “There is no widely used staging system for CCA, although it can be staged according to the American Joint Committee on Cancer (AJCC) TNM system103,104.”
> “Finally, the TNM classification misses relevant prognostic factors such as the presence of cancer-related symptoms (such as abdominal pain or malaise) or the degree of liver function impairment.”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

> “Disease stage was defined as locally advanced versus metastatic as per the American Joint Committee on Cancer staging (version 7),21 according to which intrahepatic cholangiocarcinoma with multifocal or satellite liver lesions or metastases were classified as locally advanced in the absence of extrahepatic metastatic disease.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

<a id="topic-2.2.1.5-10"></a>

###### Diagnosis: yield of comprehensive genomic profiling in biliary tract tumours

> “Reportable genomic alterations were detected in 88 patients (96.7%), whereas no reportable alteration was detected in three patients (3.3%).”
> “Potentially actionable genomic alterations were identified in 21 patients (23.1%). Expert panel-based therapeutic options were identified in 15 patients (16.5%), and genomically matched therapy was introduced in 7 patients (7.7%).”
> “Site-specific frequencies of potentially actionable alterations were highest in iCCA (17/46, 37.0%), followed by GBC (4/24, 16.7%), whereas no potentially actionable genomic alteration was identified in eCCA or ampullary tumors using this definition.”

Source: [Nakaoka et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13406710/)

<a id="topic-2.2.1.5-11"></a>

###### Diagnosis: misclassification as cancer of unknown primary

> “The nonspecific clinical presentation, absence of distinguishable localizing symptoms, and lack of definitive pathologic diagnosis—combined with the typically late diagnosis of CCA—can lead to liver-dominant carcinomas being misclassified as cancers of unknown primary (CUP) origin.”
> “Therefore, patients with CUP often face protracted diagnostic journeys, rapidly spreading metastases, and median OS ranging from two to eight months.”

Source: [Verma et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12611303/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Obstructive and biliary symptoms: jaundice from biliary tract obstruction

> “CCAs are usually asymptomatic during early stages. The most frequent symptom of pCCA and dCCA is jaundice due to biliary tract obstruction88. In iCCA, jaundice is less frequent and mostly associated with advanced disease.”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

> “Patients with pCCA and dCCA typically present with painless jaundice owing to underlying biliary obstruction.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

> “Intrahepatic disease may manifest as a liver mass or cholangitis with possible intrahepatic abscess formation as well as right upper quadrant pain related to capsular distension, whereas extrahepatic neoplasms lead to painless obstructive jaundice and cholangitis.”

Source: [Kaupp-Roberts et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5117782/)

<a id="topic-2.2.1.6-2"></a>

###### Pruritus and its consequences in malignant biliary obstruction

> “In fact, the presence of pruritus can cause severe sleep deprivation resulting in lassitude, fatigue, depression, and suicidal ideation [3]. On the other hand, in patients with better prognosis, biliary obstruction and jaundice also lead to hepatic failure and compromise the administration of chemotherapy, when clinically indicated.”

Source: [Ferraz Gonçalves et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33123850/)

<a id="topic-2.2.1.6-3"></a>

###### Pain: abdominal and right upper quadrant pain

> “Other symptoms of advanced disease include asthenia, abdominal pain, malaise, nausea, anorexia and weight loss.”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

> “Gallbladder cancer may be found incidentally at cholecystectomy; however, it may present with pain due to mass effects and may also trigger obstructive jaundice.”

Source: [Kaupp-Roberts et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5117782/)

<a id="topic-2.2.1.6-4"></a>

###### Constitutional symptoms: asthenia, anorexia, nausea, and weight loss

> “Patients with iCCA are often asymptomatic during early disease stages and develop symptoms or signs, such as abdominal pain or less commonly jaundice, during disease progression to an advanced stage.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

> “There was also a trend towards worsening of nausea and pain in the ASC arm, which remained stable in the ASC + FOLFOX arm.”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.1.6-5"></a>

###### Asymptomatic and incidental presentation

> “iCCA is an incidental finding in around 20–25% of cases88. In patients with cirrhosis, ultrasonography surveillance for HCC enables iCCA diagnosis at an asymptomatic, early stage89.”
> “However, most patients (∼70%) are diagnosed at late stages due to lack of specific symptoms104.”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

> “iCCA is often seen at presentation as an intrahepatic mass and is incidentally found in 25–30% of patients”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.6-6"></a>

###### Symptom domains captured by the disease-specific quality-of-life module

> “The QLQ-BIL21 consists of 21 questions: 3 single-item assessments relating to treatment side effects, difficulties with drainage bags/tubes and concerns regarding weight loss, in addition to 18 items grouped into 5 proposed scales: eating symptoms (4 items), jaundice symptoms (3 items), tiredness (3 items), pain symptoms (4 items) and anxiety symptoms (4 items).”

Source: [Kaupp-Roberts et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5117782/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Summary: cumulative morbidity in advanced and second-line disease

Long-term morbidity in advanced biliary tract cancer is dominated by recurrent biliary obstruction and its management, by infection, and by functional decline after progression on first-line therapy. Active symptom control in the second-line setting is defined to include biliary drainage, antibiotics, analgesia, steroids, anti-emetics, palliative radiotherapy, and transfusion of blood products. In a single-centre series of 171 participants who received a palliative biliary stent, complications occurred in 91 (53%) and cholangitis was the most frequent, in 48 (53%) of those with complications; median survival was 75.5 days. In a United States claims cohort, 69.5% of participants had an all-cause inpatient hospitalization and 65.6% a biliary-tract-cancer-related hospitalization, with a mean stay of 7 days per visit and the largest share of inpatient visits occurring during third-line therapy. Rapid decline in performance status after first-line progression limits how many participants can be treated at all.

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Ferraz Gonçalves et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33123850/); [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.7-2"></a>

###### Long-term morbidity: recurrent biliary obstruction and the content of active symptom control

> “ASC consisted of early identification and treatment of biliary-related complications and cancer-related symptom management; it could include (and was not limited to) the following as per requirements of individual patients: biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy (eg, for painful bone metastases), and transfusion of blood products.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

> “In patients with biliary obstruction, biliary drainage and subsequent treatment should be carried out; when endoscopic access is not possible, percutaneous transhepatic drainage is recommended [IV, A].”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.1.7-3"></a>

###### Long-term morbidity: complications of palliative biliary drainage

> “Insertion of a biliary stent was performed in 171 patients. The most common diagnoses were gastric and colorectal cancers, each with 42 (24%), followed by pancreatic (34 (20%)) and biliary tract cancer (25 (14%)). Most stents (155 (91%)) were placed percutaneously. Complications were seen in 91 (53%) patients and the most common was cholangitis in 48 (53%) patients, and the median survival was 75.5 days (3-1246).”
> “The 30-day mortality was 27%. Some patients had relatively long survivals: 12 (7%) lived more than 1 year, 2 (1%) more than 2 years, and one more than 3 years.”
> “The type of complications described in this study need admission to a health service for treatment of infections, insertion of another stent or other procedure, and all this have a negative impact in the quality of life of patients with a very limited life expectancy.”

Source: [Ferraz Gonçalves et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33123850/)

<a id="topic-2.2.1.7-4"></a>

###### Long-term morbidity: hospitalization burden rises with each line of therapy

> “Overall, 69.5% of patients had all-cause inpatient hospitalizations and 65.6% patients had BTC-related inpatient hospitalizations during the follow-up period. Patients stayed in hospital for a mean period of 7 days per visit. Both all-cause and BTC-related inpatient hospitalizations increased in number as the LOT advanced, with most inpatient visits (55.1%) reported during 3LOT among all LOTs (Table 3).”

Source: [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.7-5"></a>

###### Long-term morbidity: functional decline after progression on first-line therapy

> “Patients with advanced biliary tract cancer often experience a rapid decline in performance status following progression on first-line chemotherapy, and only 15–25% receive second-line therapy.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

> “In the current study, 46.0% of patients received 2LOT, which could be due to a number of reasons such as potentially high morbidity in patients who progress after 1LOT, poor performance status, or lack of effective treatment options in 2LOT.”

Source: [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.7-6"></a>

###### Long-term morbidity: recurrence after curative-intent resection

> “Tumour resection is still the only potentially curative option for these patients, although only a small percentage of patients are eligible and the percentage recurrence is high.”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Second-line advanced biliary tract cancer

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Summary: health-related quality of life in advanced and second-line disease

Robust health-related quality-of-life data in cholangiocarcinoma are sparse, which the authors of a disease primer attribute to low incidence, high lethality, limited trial enrollment until recently, and a historical lack of dedicated measurement tools. The EORTC QLQ-BIL21 was validated in 172 participants with cholangiocarcinoma and 91 with gallbladder cancer and measures eating, jaundice, tiredness, pain, and anxiety symptoms alongside the generic QLQ-C30.

In the second-line setting, the ABC-06 quality-of-life analysis found no difference between arms in time to deterioration of the global health scale (adjusted hazard ratio 0.97, 95% CI 0.48 to 1.97, P = 0.937) and found that adding FOLFOX did not worsen global, physical, social, or symptom scores, whereas the active-symptom-control arm declined across several domains including the EQ-5D utility value, which fell from 0.75 at baseline to 0.62 at month 4. In the first-line setting, neither durvalumab nor pembrolizumab added to gemcitabine and cisplatin worsened patient-reported outcomes: median time to deterioration of global health status or quality of life was 7.4 months versus 6.7 months in TOPAZ-1, and estimates were similar between arms in KEYNOTE-966.

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/); [Kaupp-Roberts et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5117782/); [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/); [Burris et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38697156/); [Yoo et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40154623/)

<a id="topic-2.2.1.8.1-2"></a>

###### Humanistic burden: sparse quality-of-life evidence in cholangiocarcinoma

> “Robust studies and data on the quality of life of patients with CCA are sparse. This paucity of information is due to the low incidence of the disease, its high lethality, the limited number of patients enrolling in clinical trials until very recently, and the lack of dedicated quality-of-life measurement tools.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.8.1-3"></a>

###### Humanistic burden: validated disease-specific instrument

> “There is no specific quality of life (QoL) measurement tool to quantify QoL in patients with biliary tract cancer. Quality of life measurement is an increasingly crucial trial end point and is now being incorporated into clinical practice.”
> “This International Multicentre Phase IV Validation Study assessed the QLQ-BIL21 module in 172 patients with cholangiocarcinoma and 91 patients with cancer of the gallbladder.”
> “The QLQ-BIL21 is a valid tool for the assessment of QoL in patients with cholangiocarcinoma and cancer of the gallbladder.”

Source: [Kaupp-Roberts et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5117782/)

<a id="topic-2.2.1.8.1-4"></a>

###### Humanistic burden: quality-of-life dynamics from baseline to month 4 in the second-line setting

| Measure | Active symptom control, baseline | Active symptom control, month 4 | Active symptom control, P value | Active symptom control plus FOLFOX, baseline | Active symptom control plus FOLFOX, month 4 | Active symptom control plus FOLFOX, P value |
| --- | --- | --- | --- | --- | --- | --- |
| EQ-5D utility value | “0.75” | “0.62” | “0.0309” | “0.77” | “0.70” | “0.6183” |
| QLQ-C30 Summary score | “77” | “64” | “0.0446” | “79” | “71” | “0.1846” |
| QLQ-C30 Physical health scale | “74” | “59” | “0.0221” | “78” | “66” | “0.1238” |
| QLQ-C30 Social function scale | “77” | “61” | “0.0272” | “76” | “65” | “0.1307” |
| QLQ-C30 Role scale | “71” | “49” | “0.0283” | “76” | “57” | “0.2713” |
| QLQ-C30 Nausea | “10” | “25” | “0.0009” | “10” | “16” | “0.4495” |
| QLQ-C30 Pain | “29” | “44” | “0.0323” | “28” | “21” | “0.2089” |

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.1.8.1-5"></a>

###### Humanistic burden: time to deterioration of global health in the second-line setting

> “Exposure to FOLFOX did not have a significant impact on the time to Global Health Scale deterioration (n = 76 participants; 36 patients ASC-alone arm; 40 patients in the FOLFOX arm), with similar TTD in both arms”
> “aHR 0.97, 95% CI 0.48-1.97, P = 0.937”
> “Addition of FOLFOX to ASC did not appear to induce worsening of the QoL parameters assessed (Table 3) at 4 months of study entry. In contrast, patients in the ASC-alone arm appeared to experience worsening of the EQ-5D utility values and most of the QLQ-C30 scales (including global, physical, social, and role scales), whereas these were stable in the FOLFOX arm.”
> “The absence of QoL deterioration with chemotherapy in this frail population highlights the importance of disease control, even in the absence of symptomatic improvement.”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.1.8.1-6"></a>

###### Humanistic burden: endpoint status, questionnaire completion, and compliance in the first-line setting

> “Patient-reported outcomes were a prespecified secondary endpoint of the trial, but these analyses were not powered for formal testing.”
> “More than 81% of participants in both treatment groups completed both questionnaires at baseline (figure 1). The proportion of participants who completed the questionnaires remained higher than 70% throughout 28 cycles of treatment (figure 1).”

Source: [Burris et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38697156/)

> “At week 18, 320 (61.5%) participants in the pembrolizumab arm completed QLQ-C30 with a 93.3% compliance rate (320 out of 343 participants) vs. 315 (60.9%) in the placebo arm with a 95.7% compliance rate (315 out of 329).”

Source: [Yoo et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40154623/)

<a id="topic-2.2.1.8.1-7"></a>

###### Humanistic burden: baseline symptom burden in the first-line setting

> “Mean global health status or QOL scores for participants at baseline were 63·0 (95% CI 60·7–65·3) in the durvalumab group and 65·7 (63·3–68·1) in the placebo group.”
> “Symptoms with mean scores greater than 20 in either treatment group were anxiety, fatigue, tiredness, insomnia, pain, appetite loss, weight loss, and abdominal pain (table).”

Source: [Burris et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38697156/)

<a id="topic-2.2.1.8.1-8"></a>

###### Humanistic burden: patient-reported outcomes in the first-line setting

> “Median time to deterioration of global health status or quality of life was 7·4 months (95% CI 5·6 to 8·9) in the durvalumab group and 6·7 months (5·6 to 7·9) in the placebo group (hazard ratio 0·87 [95% CI 0·69 to 1·12]).”
> “The adjusted mean change from baseline scores for all patient-reported outcomes did not meet the predefined threshold of an absolute change of 10 points or greater.”
> “In a post-hoc analysis, the HR for time to deterioration of global health status or QOL in the durvalumab group compared with the placebo group was 0·95 (0·74–1·24) up to 7 months, and 0·45 (0·22–0·91) after 7 months (figure 2A).”

Source: [Burris et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38697156/)

> “Time to confirmed deterioration estimates were also similar between arms, including for global health status/quality of life (median not reached [NR] in the pembrolizumab arm vs. 21.2 months in the placebo arm; hazard ratio [HR] 0.86, 95% CI 0.70-1.07); jaundice (NR vs. NR; HR 1.20, 95% CI 0.94-1.54), and pain (NR vs. NR; HR 0.79, 95% CI 0.59-1.05).”
> “For the six prespecified domains, similar results between treatment arms were observed in the LSM change from baseline to week 18 (Table 1), including GHS/QoL (difference = 0.04, 95% CI -2.52 to 2.60; nominal p = 0.98), physical functioning (difference = 1.24; 95% CI -1.42 to 3.90; nominal p = 0.36) and role functioning (difference = 2.68, 95% CI -0.76 to 6.11; nominal p = 0.13).”
> “Comparable changes from baseline to week 18 between the two treatment arms were also seen for jaundice (difference = 0.26; 95% CI -1.35 to 1.87; nominal p = 0.75) and pain (difference = -1.87, 95% CI -4.26 to 0.53; nominal p = 0.13) symptom scale scores, as well as EQ-5D-5L VAS (difference = 0.14; 95% CI -2.18 to 2.46; nominal p = 0.91).”
> “The PRO endpoints were exploratory and were not powered to provide statistical significance nor adjusted for multiple comparisons, and therefore the results should be interpreted with caution.”

Source: [Yoo et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40154623/)

<a id="topic-2.2.1.8.1-9"></a>

###### Humanistic burden: deterioration of global health in relation to objective response and survival

> “Median time to deterioration of global health status or QOL was longest for participants with a complete or partial response and shortest for participants with progressive disease (appendix p 9), suggesting that response could be associated with improved QOL.”
> “The HR for time to deterioration of global health status or QOL after 7 months suggested that the improved overall survival associated with durvalumab, gemcitabine, and cisplatin compared with placebo gemcitabine, and cisplatin could be accompanied by improved QOL.”

Source: [Burris et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38697156/)

<a id="topic-2.2.1.8.1-10"></a>

###### Humanistic burden: perspective of a patient and advocate

> “All patients, including myself, desire to increase our survival time. However, I came to a point in my journey in which quality of life became more important than the quantity of life, and my fellow patients agree with this sentiment. I came to this decision because my quality of life declined after 2 years of undergoing chemotherapy, and I had no desire to continue.”
> “Because there is no proven treatment and minimal options for CCA, patients are willing to try treatments that have no guarantee of working.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Summary: costs and resource use in advanced biliary tract cancer

In a United States commercially insured cohort of participants with advanced biliary tract cancer treated before immuno-oncology regimens were approved, mean per-patient-per-month all-cause costs were $18,274 overall, of which approximately 84% ($15,296) were biliary-tract-cancer-related. Costs rose with each line of therapy, from $19,589 in first line to $22,617 in second line and $33,534 in third line. Outpatient and inpatient utilization were the main cost drivers, and approximately 70% of participants had at least one inpatient visit. Earlier estimates cited in the same study were $7,743 per-patient-per-month for advanced cholangiocarcinoma-associated costs after first-line failure and $20,696 per-patient-per-month for all-cause biliary tract cancer management. In a separate claims analysis of participants receiving pemigatinib, mean per-patient-per-month medical costs were $13,444 for those with a prior cancer-of-unknown-primary diagnosis and $9,881 for those without.

Source: [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/); [Verma et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12611303/)

<a id="topic-2.2.1.8.2-2"></a>

###### Economic burden: per-patient-per-month costs by line of therapy

> “The mean PPPM costs for the overall population were $18,274 for all-cause costs, of which approximately 84% ($15,296) comprised BTC-related costs.”
> “The total mean (SD) PPPM all-cause costs by LOT were $19,589 ($22,603) for 1LOT, $22,617 ($19,302) for 2LOT and $33,534 ($40,588) for 3LOT.”
> “We found that total all-cause PPPM cost was $19,589 during 1LOT, increasing to $22,617 and $33,534 as the treatment advanced to 2LOT and 3LOT, respectively, with >80% of PPPM costs only related to BTC.”
> “The primary driver of costs across all three LOTs was outpatient (including antineoplastic therapy visits) and inpatient utilization followed by outpatient pharmaceutical costs.”

Source: [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.8.2-3"></a>

###### Economic burden: previously published cost estimates

> “One study focused on costs of second-line therapies in selected patients with advanced cholangiocarcinoma who experienced failure of a first-line therapy containing either gemcitabine or fluorouracil; the total mean per-patient-per-month (PPPM) advanced cholangiocarcinoma-associated healthcare costs were $7,743 [20]. Another study noted high total all-cause healthcare costs of $20,696 PPPM for the management of BTC; however, this study did not account for disease stage or 1LOT using a validated clinical data source [21].”

Source: [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.8.2-4"></a>

###### Economic burden: complications as cost drivers

> “Healthcare professionals could implement strategies to identify and prevent some of these complications at an early stage and initiate pre-emptive discussions regarding advanced treatment options and patient preferences for further management to limit excess costs.”
> “In addition to the unmet treatment needs of patients with advanced BTC, the care costs pose a significant burden on patients and payers that has increased over time [20].”

Source: [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.8.2-5"></a>

###### Economic burden: resource use and cost in a targeted-therapy cohort

> “CUP was associated with significantly higher prevalence of metastatic disease (100.0% vs 63.6%), per patient per month (PPPM) ambulatory HCRU (8.2 vs 5.5), and ambulatory costs ($8584 vs $5308). Medical costs averaged $13 444 vs $9881 PPPM for CUP and non-CUP, respectively (P = .066). Median OS was significantly shorter with CUP (10.2 vs 30.7 months).”

Source: [Verma et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12611303/)

<a id="topic-2.2.1.8.2-6"></a>

###### Economic burden: direct medical costs in an employed population

> “Patients with iCCA vs. eCCA had higher inpatient, outpatient medical, outpatient pharmacy, and all-cause healthcare costs PPPM.”
> “Patients with CCA had high productivity losses, indirect costs, and medical costs. Outpatient services costs contributed greatly to the higher healthcare expenditure observed in patients with iCCA vs. eCCA.”
> “Whereas reported costs from the previous analysis were higher than the mean all-cause healthcare costs (range: $10,321–$11,175) and inpatient costs (range: $3,798–$4,883) PPPM across CCA cohorts in our analysis, these disparities may be owing to differences in the patient inclusion criteria of each analysis; selecting for patients with previously treated CCA may have resulted in an older patient population with more advanced disease.”

Source: [Parasuraman et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36883994/)

<a id="topic-2.2.1.8.2-7"></a>

###### Economic burden: inpatient admission rates in an employed cholangiocarcinoma cohort

> “The percentage of patients with CCA, iCCA, or eCCA being admitted to the hospital were similar across each cohort of absenteeism (75.7, 72.1, and 78.0%, respectively), short-term disability (75.9, 73.9, and 75.3%, respectively), and long-term disability (73.8, 71.2, and 74.5%, respectively).”

Source: [Parasuraman et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36883994/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Second-line advanced biliary tract cancer on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Summary: work loss, indirect costs, and family financial exposure

Cholangiocarcinoma imposes measurable work loss and indirect costs on working-age households. In a United States retrospective claims analysis of 1,065 participants with cholangiocarcinoma who had work absence and disability benefits eligibility, mean all-cause days absent per patient per month for illness were 6.0 for intrahepatic and 4.3 for extrahepatic disease, and 12.9% and 6.6% respectively had at least one cholangiocarcinoma-related short-term disability claim. Median indirect costs per patient per month from absenteeism, short-term disability, and long-term disability were $622, $635, and $690 for intrahepatic disease and $304, $589, and $465 for extrahepatic disease. A patient and advocate writing in a disease primer describes declining a first-line clinical trial because insurance would not cover the associated standard-of-care costs and she did not want to put her family in financial distress, and describes travel for trial participation as a source of financial burden.

Source: [Parasuraman et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36883994/); [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.8.3-2"></a>

###### Economic impact on families: productivity loss and indirect costs

> “One thousand and sixty-five patients with CCA were included (iCCA: n = 624 [58.6%]; eCCA: n = 380 [35.7%]). The mean age was 51.9-53.9 years across cohorts. In patients with iCCA and eCCA, respectively, the number of mean all-cause days absent PPPM for illness was 6.0 and 4.3, and 12.9 and 6.6% had ≥1 CCA-related short-term disability claim. Median indirect costs PPPM owing to absenteeism, short-term disability, and long-term disability, respectively, in patients with iCCA were $622, $635, and $690, and $304, $589, and $465 in patients with eCCA.”
> “Cholangiocarcinoma (CCA) is associated with poor prognosis. Healthcare-related management likely presents a substantial economic burden associated with time away from work in patients with CCA.”
> “In the absenteeism, short-term disability, and long-term disability cohorts, respectively, mean indirect costs associated with productivity loss contributed to 8.6, 7.2, and 6.7% of the total costs ($11,287, $11,887, and $11,977).”
> “This suggests that patients in our analysis are more economically advantaged than the overall population of the United States, many of whom do not have access to paid sick leave or are not provided with insurance by their employers. Thus, our analysis may underestimate the productivity losses within the overall population of the United States.”

Source: [Parasuraman et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36883994/)

<a id="topic-2.2.1.8.3-3"></a>

###### Economic impact on families: out-of-pocket exposure and travel for clinical trials

> “Unfortunately, my insurance at that time would not cover the standard-of-care costs that go along with being in a clinical trial. I chose not to join the trial because I did not want to put my family in financial distress.”
> “Patients most likely will have to travel to be able to participate in a trial and that, in turn, causes other issues, such as financial burden.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.8.3-4"></a>

###### Economic impact on families: household income relative to the cost of oral targeted therapy

> “According to the U.S. Census Bureau, the average U.S. household income in 2022 was $105,555, while the median U.S. household income was $74,580. Without private or public health insurance, the kinase inhibitor costs are prohibitive.”

Source: [Roskoski (2024)](https://pubmed.ncbi.nlm.nih.gov/38096958/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Summary: cost consequences of molecular profiling and of diagnostic delay

Second-line treatment selection in biliary tract cancer depends on molecular profiling, because approved second-line targeted options are restricted to IDH1 mutations, FGFR2 fusions, MSI-H or dMMR tumours, and BRAF V600E tumours, and the Pan-Asian adapted ESMO guideline recommends molecular analysis in advanced disease considered suitable for systemic treatment. The economic return on that testing is limited by yield: in 91 biliary tract tumours profiled at a single centre, comprehensive genomic profiling produced potentially actionable findings in 23.1% and genomically matched therapy in 7.7%. The cost of failing to establish a primary site is measurable. Among 221 participants with cholangiocarcinoma initiating pemigatinib, those with a prior cancer-of-unknown-primary diagnosis had higher ambulatory resource use (8.2 versus 5.5 visits per patient per month), higher ambulatory costs ($8,584 versus $5,308), mean medical costs of $13,444 versus $9,881 per patient per month, and shorter median overall survival (10.2 versus 30.7 months); the authors conclude that reflexive genomic testing should be encouraged for all participants with cancer of unknown primary.

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/); [Nakaoka et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13406710/); [Verma et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12611303/)

<a id="topic-2.2.1.8.4-2"></a>

###### Economic impact of diagnostic testing: cost consequences of an unresolved primary site

> “CUP was associated with significantly higher prevalence of metastatic disease (100.0% vs 63.6%), per patient per month (PPPM) ambulatory HCRU (8.2 vs 5.5), and ambulatory costs ($8584 vs $5308). Medical costs averaged $13 444 vs $9881 PPPM for CUP and non-CUP, respectively (P = .066). Median OS was significantly shorter with CUP (10.2 vs 30.7 months).”
> “With the advent of targeted treatments for gene-altered CCA, reflexive genomic testing should be encouraged for all patients with CUP.”
> “Reflexive genomic testing upon CUP diagnosis may help reduce delays in identifying actionable targets and initiating appropriate targeted therapy.”

Source: [Verma et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12611303/)

<a id="topic-2.2.1.8.4-3"></a>

###### Economic impact of diagnostic testing: yield of comprehensive genomic profiling

> “This retrospective single-center observational study included 91 patients with BTTs who underwent CGP.”
> “Potentially actionable genomic alterations were identified in 21 patients (23.1%). Expert panel-based therapeutic options were identified in 15 patients (16.5%), and genomically matched therapy was introduced in 7 patients (7.7%).”
> “CGP revealed a heterogeneous genomic landscape across BTT subtypes and provided clinically actionable information in a limited but meaningful subset of patients. The practical utility of CGP was the greatest in selected molecular subsets, particularly iCCA.”

Source: [Nakaoka et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13406710/)

<a id="topic-2.2.1.8.4-4"></a>

###### Economic impact of diagnostic testing: guideline requirement for molecular analysis

> “Molecular analysis is recommended in advanced disease considered suitable for systemic treatment [I, A]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Gemcitabine and Cisplatin Plus an Immune Checkpoint Inhibitor

<a id="topic-2.2.2.1.1-1"></a>

###### ESMO recommendation: first-line chemoimmunotherapy

> “Cisplatin–gemcitabine–durvalumab and cisplatin–gemcitabine–pembrolizumab are recommended as first-line therapy [I, A].”
> “Cisplatin–gemcitabine combined with either pembrolizumab or durvalumab is a viable option for first-line treatment.”
> “At present, there are no discernible clinical, biochemical or molecular biomarkers, nor any notable differences in efficacy or toxicity, favouring one immune checkpoint inhibitor over the other.”

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)

<a id="topic-2.2.2.1.1-2"></a>

###### Durvalumab plus gemcitabine and cisplatin: TOPAZ-1 phase 3 results

> “Patients with advanced biliary tract cancer have a poor prognosis, and first-line standard of care (gemcitabine plus cisplatin) has remained unchanged for more than 10 years.”
> “The hazard ratio for overall survival was 0.80 (95% confidence interval [CI], 0.66 to 0.97; P=0.021).”
> “The estimated 24-month overall survival rate was 24.9% (95% CI, 17.9 to 32.5) for durvalumab and 10.4% (95% CI, 4.7 to 18.8) for placebo.”
> “Objective response rates were 26.7% with durvalumab and 18.7% with placebo.”

Source: [Oh et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319896/)

<a id="topic-2.2.2.1.1-3"></a>

###### Pembrolizumab plus gemcitabine and cisplatin: KEYNOTE-966 phase 3 results

> “Median overall survival was 12·7 months (95% CI 11·5-13·6) in the pembrolizumab group versus 10·9 months (9·9-11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72-0·95]; one-sided p=0·0034 [significance threshold, p=0·0200]).”
> “At the first interim analysis, 153 (29% [95% CI 25 to 33]) of 533 participants in the pembrolizumab group and 153 (29% [25 to 33]) of 536 participants in the placebo group had a complete or partial response (table 2).”
> “Median duration of response was 9·7 months (95% CI 6·9 to 12·2) in the pembrolizumab group and 6·9 months (5·7 to 8·2) in the placebo group.”

Source: [Kelley et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37075781/)

<a id="topic-2.2.2.1.1-4"></a>

###### Subsequent anticancer therapy after first-line gemcitabine and cisplatin plus an immune checkpoint inhibitor

> “Median (95% CI) time to first SAT was longer for participants in the durvalumab arm (18.7 [13.2–42.2] months) vs. the placebo arm (12.3 [11.3–24.1] months) (HR 0.92; 95% CI 0.75–1.13; Fig. S2).”
> “In the small number of participants who received targeted therapies, the mean time to death or censoring from starting targeted therapy for durvalumab vs. placebo was 21.4 vs. 7.5 months (n = 4 vs. n = 2) with FGFR inhibitors and 11.3 vs. 8.4 months (n = 5 vs. n = 5) with IDH1 inhibitors, when given as subsequent therapy (Fig. S4).”

Source: [Oh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40381735/)

> “253 (47%) of 533 participants in the pembrolizumab group and 261 (49%) of 536 participants in the placebo group had received one or more subsequent anticancer therapies”

Source: [Kelley et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37075781/)

<a id="topic-2.2.2.1.1-5"></a>

###### Alternative first-line regimens for reduced fitness or organ dysfunction

> “Oxaliplatin or carboplatin may be substituted for cisplatin when renal or auditory function is of concern, while gemcitabine plus S-1 can be an option for patients who present with or are susceptible to peripheral sensory neuropathy [II, B]”
> “Gemcitabine monotherapy may be used in patients with a PS of 2 [IV, B]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.2.1.1-6"></a>

###### Toxicity of first-line chemotherapy intensification

> “Higher rates of treatment-related toxicity are observed with the addition of a third cytotoxic agent to gemcitabine–cisplatin in all of these regimens.”

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)

<a id="topic-2.2.2.1.1-7"></a>

###### Grade 3 or 4 adverse events and treatment discontinuations in KEYNOTE-966

> “In the as-treated population, the maximum adverse event grade was 3 to 4 in 420 (79%) of 529 participants in the pembrolizumab group and 400 (75%) of 534 in the placebo group; 369 (70%) participants in the pembrolizumab group and 367 (69%) in the placebo group had treatment-related adverse events with a maximum grade of 3 to 4.”
> “31 (6%) participants in the pembrolizumab group and 49 (9%) in the placebo group died due to adverse events, including eight (2%) in the pembrolizumab group and three (1%) in the placebo group who died due to treatment-related adverse events.”
> “Adverse events led to discontinuation of one or more study drugs in 138 (26%) participants in the pembrolizumab group and in 122 (23%) participants in the placebo group; discontinuation of all study drugs occurred in 35 (7%) participants in the pembrolizumab group and 39 (7%) in the placebo group.”

Source: [Kelley et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37075781/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Fluoropyrimidine-Based Second-line Chemotherapy

<a id="topic-2.2.2.1.2-1"></a>

###### Guideline recommendation: FOLFOX as the second-line standard of care

> “FOLFOX is the standard of care in the second-line setting after cisplatin-gemcitabine-based treatment”
> “Irinotecan monotherapy or irinotecan- or liposomal irinotecan-based combination therapy may be considered [III, B]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

> “For patients who progressed after frontline therapy and lack actionable alterations, fluoropyrimidine plus oxaliplatin and fluoropyrimidine plus liposomal irinotecan are recommended second-line options, supported by ABC-06 and NIFTY, respectively.”
> “The primary endpoint, median OS, was significantly improved with ASC plus FOLFOX over ASC alone (Table 1B). The median PFS was 4.0 months, and the ORR was 4.9% in the FOLFOX arm.”

Source: [Yoon and Yoo (2026)](https://pubmed.ncbi.nlm.nih.gov/41429598/)

> “FOLFOX is the SoC in the second-line setting after cisplatin–gemcitabine [I, A; ESMO-MCBS v1.1 score: 1; no specific licensed indication in BTC].”
> “Second-line ChT has previously been used ad hoc by clinicians with limited knowledge of the magnitude of benefit.”
> “Evidence for irinotecan-based therapies is currently limited.”

Source: [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/)

<a id="topic-2.2.2.1.2-2"></a>

###### FOLFOX versus active symptom control: ABC-06 phase 3 results

> “Overall survival was significantly longer in the ASC plus FOLFOX group than in the ASC alone group, with a median overall survival of 6·2 months (95% CI 5·4–7·6) in the ASC plus FOLFOX group versus 5·3 months (4·1–5·8) in the ASC alone group (adjusted hazard ratio 0·69 [95% CI 0·50–0·97]; p=0·031).”
> “Objective response was observed in four (5%) of 81 patients in the ASC plus FOLFOX group: one (1%) patient had a complete response and three (4%) patients had a partial response.”
> “Grade 3–5 adverse events were reported in 42 (52%) of 81 patients in the ASC alone group and 56 (69%) of 81 patients in the ASC plus FOLFOX group, including three chemotherapy-related deaths (one each due to infection, acute kidney injury, and febrile neutropenia).”
> “Based on these findings, FOLFOX should become standard-of-care chemotherapy in second-line treatment for advanced biliary tract cancer and the reference regimen for further clinical trials.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

<a id="topic-2.2.2.1.2-3"></a>

###### Liposomal irinotecan plus fluorouracil and leucovorin: NIFTY randomized phase 2b trial

> “At a median follow-up of 11·8 months (IQR 7·7-18·7), the median BICR-assessed progression-free survival was significantly longer in the liposomal irinotecan plus fluorouracil and leucovorin group (7·1 months, 95% CI 3·6-8·8) than in the fluorouracil and leucovorin group (1·4 months, 1·2-1·5; hazard ratio 0·56, 95% CI 0·39-0·81; p=0·0019).”
> “Liposomal irinotecan plus fluorouracil and leucovorin could be considered a standard-of-care second-line therapy for advanced biliary tract cancer.”
> “The discordance rate for the date of tumour progression between the investigator and the BICR assessments was 30% (52 of 174; appendix 2 pp 5–8).”
> “the possibility of overestimation in the median progression-free survival by BICR assessment cannot be excluded.”

Source: [Yoo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34656226/)

<a id="topic-2.2.2.1.2-4"></a>

###### Liposomal irinotecan plus fluorouracil and leucovorin: NALIRICC randomized phase 2 trial

> “Median progression-free survival was 2·6 months (95% CI 1·7-3·6) in the nanoliposomal irinotecan group and 2·3 months (1·6-3·4) in the control group (hazard ratio [HR] 0·87 [0·56-1·35]).”
> “The addition of nanoliposomal irinotecan to fluorouracil plus leucovorin did not improve progression-free survival or overall survival and was associated with higher toxicity compared with fluorouracil plus leucovorin.”

Source: [Vogel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38870977/)

<a id="topic-2.2.2.1.2-5"></a>

###### Sources of discordance between the NIFTY and NALIRICC results

> “Differences in sample size (174 vs. 100), iCCA proportion (64% vs. 43%), ethnicity (Asian vs. White), and more frequent early treatment discontinuations due to toxicity in NALIRICC may have contributed to the discordant results [28].”

Source: [Yoon and Yoo (2026)](https://pubmed.ncbi.nlm.nih.gov/41429598/)

<a id="topic-2.2.2.1.2-6"></a>

###### Pooled individual patient data from NIFTY and NALIRICC

> “Current standard of care for second-line therapy in patients with advanced biliary tract cancer (BTC) is FOLFOX.”
> “The nal-IRI plus 5-FU/LV group showed significantly longer median PFS (3.6 months [95% CI 2.7-4.4] vs. 1.8 months [95% CI 1.5-2.6]; hazard ratio 0.65, p <0.001).”
> “There was no statistically significant difference in OS (median 8.1 vs. 6.1 months, HR 0.77, p = 0.051).”
> “However, nal-IRI plus 5-FU/LV may be considered a viable alternative to second-line FOLFOX for patients of East Asian ethnicity or those deemed unfit for FOLFOX (e.g. due to severe peripheral neuropathy caused by prior platinum-based therapy).”

Source: [Yoo et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40147791/)

Additional sources: [Benson et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40930144/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Taxane-Based Chemotherapy

<a id="topic-2.2.2.1.3-1"></a>

###### Addition of nab-paclitaxel to first-line gemcitabine and cisplatin: SWOG S1815 phase 3 trial

> “Median OS with GAP was 14.0 months (95% CI, 12.4 to 16.1) and 13.6 months with GC (95% CI, 9.7 to 16.6); hazard ratio (HR), 0.91 (95% CI, 0.72 to 1.14); P = .41.”
> “The addition of a taxane in the GAP regimen to the standard gemcitabine-cisplatin regimen did not improve OS in newly diagnosed BTC.”

Source: [Shroff et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11798714/)

<a id="topic-2.2.2.1.3-2"></a>

###### Paclitaxel use in later-line practice: French single-center series of 256 participants

> “Treatment distribution was as follows: FOLFIRI (n = 51, 20%), paclitaxel (n = 43, 17%), combinations of 5-FU cisplatin/FOLFOX (n = 32, 13%), molecularly targeted therapy (n = 65, 25%) and others (n = 63, 25%).”
> “OS was 13 months with paclitaxel and 7 months with FOLFIRI (P = 0.03).”

Source: [Boilève et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13459572/)

<a id="topic-2.2.2.1.3-3"></a>

###### Nab-paclitaxel-based second-line therapy: real-world cohort of 84 participants

> “Second-line options for biliary tract cancer (BTC) are limited. While nab-paclitaxel has demonstrated certain antitumor activity, evidence remains scarce.”
> “Among 84 patients (41 in the chemo-anti-PD-(L)1 group and 43 in the chemotherapy group), the median OS was 15.17 months (95% confidence interval (CI), 12.63-21.43), median PFS was 5.40 months (95% CI, 3.23-8.03), objective response rate (ORR) was 21.43% (95% CI, 13.22-31.74), and disease control rate (DCR) was 60.71% (95% CI, 49.45-71.20).”

Source: [Zhou et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12663050/)

<a id="topic-2.2.2.1.3-4"></a>

###### Rationale for paclitaxel as the COMPANION-002 comparator

> “Paclitaxel was chosen based on the safety and efficacy data from this phase Ib study.”
> “The primary end point of the phase II study was overall response rate (ORR) and the ORR was 37.5% (n = 9/24 patients).”
> “Among 11 patients treated in the second-line, the ORR was 63.6% (n = 7/11) versus 15% (n = 2/13) among patients treated in the third-line setting.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 FGFR2 Fusion-Directed Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### Guideline recommendations for FGFR inhibition after progression

> “Futibatinib [ESMO-Magnitude of Clinical Benefit (MCBS) v1.1 score: 3] and pemigatinib (ESMO-MCBS v1.1 score: 2) are recommended in patients with FGFR2 fusions or rearrangements who have progressed after one or more prior lines of systemic therapy [III, A; ESCAT score: I-B].”
> “These findings led to both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approval of pemigatinib and futibatinib.”

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)

> “FGFR inhibitors are recommended for the treatment of patients with FGFR2 fusions who have progressed after ≥1 prior line of systemic therapy [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-B]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.2.1.4-2"></a>

###### Prevalence of FGFR2 fusions and rearrangements and their detection

> “Fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements occur in up to 14% of patients with intrahepatic cholangiocarcinoma.”
> “Exploratory ctDNA analysis identified FGFR2 fusions or rearrangements in 83 of the 95 patients (87%) evaluated”

Source: [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/)

<a id="topic-2.2.2.1.4-3"></a>

###### Pemigatinib: FIGHT-202 final analysis

> “The ORR in cohort A was 37.0% (95% confidence interval 27.9% to 46.9%); complete and partial responses were observed in 3 and 37 patients, respectively.”
> “Median DOR was 9.1 (6.0-14.5) months; median PFS and OS were 7.0 (6.1-10.5) months and 17.5 (14.4-22.9) months, respectively.”
> “The most common TEAEs of any grade were hyperphosphatemia (58.5%), alopecia (49.7%), and diarrhea (47.6%).”

Source: [Vogel et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11190465/)

<a id="topic-2.2.2.1.4-4"></a>

###### Futibatinib: FOENIX-CCA2 phase 2 trial

> “A total of 43 of 103 patients (42%; 95% confidence interval, 32 to 52) had a response, and the median duration of response was 9.7 months.”
> “At a median follow-up of 17.1 months, the median progression-free survival was 9.0 months and overall survival was 21.7 months.”
> “Common treatment-related grade 3 adverse events were hyperphosphatemia (in 30% of the patients), an increased aspartate aminotransferase level (in 7%), stomatitis (in 6%), and fatigue (in 6%).”
> “Overall, treatment-related adverse events led to dose interruptions in 52 patients (50%) and dose reductions in 56 patients (54%).”

Source: [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/)

<a id="topic-2.2.2.1.4-5"></a>

###### Acquired resistance to FGFR inhibition and next-generation agents

> “Cholangiocarcinoma is a rare, aggressive cancer often driven by FGFR2 fusions, which are targetable with inhibitors such as pemigatinib and futibatinib. However, resistance frequently develops due to acquired FGFR2 mutations.”
> “Among 51 patients included in the efficacy evaluable set, the objective response rate was 6·3% (95% CI 0·2-30·2; one confirmed partial response) in cohort A1, 30·0% (6·7-65·3; three confirmed partial responses) in cohort A2, 23·1% (5·0-53·8; three confirmed partial responses) in cohort B, and 0% in cohort C.”

Source: [Javle et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41349554/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 IDH1 Inhibition

<a id="topic-2.2.2.1.5-1"></a>

###### Guideline recommendation for ivosidenib

> “Ivosidenib is recommended for the treatment of patients with CCA and IDH1 mutations who have progressed after ≥1 prior line of systemic therapy [I, A; ESMO-MCBS v1.1 score: 2; ESCAT score: I-A; FDA approved, not EMA approved]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.2.1.5-2"></a>

###### Ivosidenib versus placebo: ClarIDHy progression-free survival

> “Progression-free survival was significantly improved with ivosidenib compared with placebo (median 2·7 months [95% CI 1·6-4·2] vs 1·4 months [1·4-1·6]; hazard ratio 0·37; 95% CI 0·25-0·54; one-sided p<0·0001).”

Source: [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523268/)

<a id="topic-2.2.2.1.5-3"></a>

###### Ivosidenib versus placebo: ClarIDHy final overall survival

> “Median OS was 10.3 months (95% CI, 7.8-12.4 months) with ivosidenib vs 7.5 months (95% CI, 4.8-11.1 months) with placebo (hazard ratio, 0.79 [95% CI, 0.56-1.12]; 1-sided P = .09).”
> “When adjusted for crossover, median OS with placebo was 5.1 months (95% CI, 3.8-7.6 months; hazard ratio, 0.49 [95% CI, 0.34-0.70]; 1-sided P < .001).”

Source: [Zhu et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8461552/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 HER2-Directed Therapy

<a id="topic-2.2.2.1.6-1"></a>

###### HER2 alteration frequency and testing in biliary tract cancer

> “HER2 alterations, comprising amplifications and mutations, as well as human epidermal growth factor receptor 2 (HER2) protein overexpression, can be found in ∼5%-10% of BTC cases, with a higher prevalence observed in extrahepatic CCA and gallbladder carcinoma.”
> “Most clinical trials focus on patients with HER2 overexpression and HER2 amplification, yet there are currently no standardised criteria for assessing HER2 status in BTC and no specific test can be recommended.”

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)

<a id="topic-2.2.2.1.6-2"></a>

###### HER2 amplification yield at screening and the assay defining eligibility in HERIZON-BTC-01

> “Between Sept 15, 2020, and March 16, 2022, 847 patients were pre-screened for HER2 amplification and 171 (20%) had HER2-amplified tumours, of which 131 (77%) entered study screening and 87 (66%) were enrolled.”
> “HER2 gene amplification status was determined by the VENTANA HER2 Dual ISH DNA Probe Cocktail assay (Ventana Medical Systems, Tuscon, AZ, USA). HER2 gene status was classified as non-amplified (HER2/Chr17 ratio <2·0) or amplified (HER2/Chr17 ratio ≥2·0).”

Source: [Harding et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37276871/)

<a id="topic-2.2.2.1.6-3"></a>

###### Guideline recommendations for HER2-directed therapy after progression

> “Zanidatamab is recommended in patients with previously treated HER2-positive disease [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C; FDA approved, not EMA approved].”
> “Trastuzumab deruxtecan should be considered in patients with HER2 overexpression and/or HER2 amplification who have progressed on or are intolerant to prior treatment [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C; FDA approved, not EMA approved].”
> “Zanidatamab is now FDA approved for previously treated, unresectable or metastatic HER2-positive BTC.”

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)

> “HER2-directed therapies can be considered in patients with HER2 overexpression/amplification who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.2.1.6-4"></a>

###### Zanidatamab: HERIZON-BTC-01 phase 2b trial

> “Confirmed objective responses by independent central review were observed in 33 patients in cohort 1 (41·3% [95% CI 30·4-52·8]).”
> “The median duration of response for the 33 patients in cohort 1 with a confirmed objective response was 12·9 months (95% CI 6·0–not estimable; range 1·5–16·9+) with 16 (49%) patients having ongoing responses at the time of the data cutoff (figure 2B; appendix p 5). No responses to zanidatamab were observed in cohort 2.”
> “The median progression-free survival by independent central review in cohort 1 was 5·5 months (95% CI 3·7–7·2; range 0·3–18·5+; table 2; appendix p 6). Overall survival at 9 months was 69·9% (95% CI 57·8–79·1) for cohort 1; median overall survival data were immature at the time of data cutoff.”
> “16 patients (18%) had grade 3 treatment-related adverse events; of these, diarrhoea (four [5%] patients), ejection fraction decreased (three [3%]), and anaemia (two [2%]) occurred in more than one patient. No grade 4 or grade 5 treatment-related adverse events were reported.”

Source: [Harding et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37276871/)

<a id="topic-2.2.2.1.6-5"></a>

###### Trastuzumab deruxtecan: DESTINY-PanTumor02 biliary tract cohort and HER2 IHC 3+ population

> “In patients with central HER2 IHC 3+ expression (n = 75), the ORR was 61.3% (95% CI, 49.4 to 72.4), the median DOR was 22.1 months (95% CI, 9.6 to not reached), the median PFS was 11.9 months (95% CI, 8.2 to 13.0), and the median OS was 21.1 months (95% CI, 15.3 to 29.6).”
> “Grade ≥3 drug-related adverse events were observed in 40.8% of patients; 10.5% experienced adjudicated drug-related interstitial lung disease (ILD), with three deaths.”

Source: [Meric-Bernstam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10730032/)

<a id="topic-2.2.2.1.6-6"></a>

###### Tucatinib plus trastuzumab: SGNTUC-019 biliary tract cancer cohort

> “The cORR was 46.7% (90% CI, 30.8 to 63.0), with a disease control rate of 76.7% (90% CI, 60.6 to 88.5).”
> “The median duration of response and progression-free survival were 6.0 months (90% CI, 5.5 to 6.9) and 5.5 months (90% CI, 3.9 to 8.1), respectively.”
> “At data cutoff, 15 patients (50.0%) had died, and the estimated 12-month overall survival rate was 53.6% (90% CI, 36.8 to 67.8).”

Source: [Nakamura et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10730072/)

Additional sources: [Pant et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41264278/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Tumor-Agnostic Targeted and Immune Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Frequency of tumor-agnostic targets in biliary tract cancer

> “Disease-agnostic approved agents are available for tumors with BRAF V600E mutations (4–5% frequency in BTC), NTRK fusions (<1%), RET fusions (<1%), and/or microsatellite instability (1–2%)”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

> “NTRK fusions occur in <0.1% of BTC cases.”
> “Because of the very low prevalence of these alterations, the respective inhibitors have only been evaluated in basket trials.”

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)

<a id="topic-2.2.2.1.7-2"></a>

###### Guideline recommendations for BRAF, NTRK, RET, MSI-H, and TMB-high disease

> “Dabrafenib-trametinib is recommended for the treatment of patients with BRAFV600E mutations who have progressed after ≥1 prior line of systemic therapy [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-B; FDA approved, not EMA approved]”
> “NTRK inhibitors are recommended in patients with NTRK fusions who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C]”
> “Selpercatinib can be considered in patients with RET fusions who have progressed on or are intolerant to prior treatment [III; A; ESMO-MCBS v1.1 score for solid tumours with a RET fusion: 3; ESCAT score: I-C; FDA approved, not EMA approved]”
> “Pembrolizumab is recommended in patients with MSI-H/dMMR who have progressed on or are intolerant to prior non-immune checkpoint inhibitor-containing treatment [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C]”
> “Pembrolizumab can be considered in patients with TMB-H tumours who have progressed on or are intolerant to prior non-immune checkpoint inhibitor-containing treatment [IV; A; ESMO-MCBS v1.1 score for pembrolizumab in TMB-H solid tumours: 3; ESCAT Score: I-C]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

> “Entrectinib (ESMO-MCBS v1.1 score: 3), larotrectinib (ESMO-MCBS v1.1 score: 3) and repotrectinib (not EMA or FDA approved) are recommended in patients with NTRK fusions who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C].”
> “Selpercatinib should be considered in patients with RET fusions who have progressed on or are intolerant to prior treatment [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C].”

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)

<a id="topic-2.2.2.1.7-3"></a>

###### Dabrafenib plus trametinib: ROAR biliary tract cancer cohort

> “An investigator-assessed overall response was achieved by 22 (51%, 95% CI 36-67) of 43 patients.”
> “An independent reviewer-assessed overall response was achieved by 20 (47%, 95% CI 31-62) of 43 patients.”
> “The median duration of response in 22 patients with an investigator-assessed overall response was 9 months (95% CI 6–14).”
> “Median progression-free survival by investigator assessment was 9 months (95% CI 5–10; figure 2A). Overall survival was 84% (95% CI 69–92) at 6 months, 56% (38–71) at 12 months, and 36% (19–53) at 24 months.”
> “15 (35%) patients had adverse events that led to dose reduction, 24 (56%) patients had adverse events that led to dose interruption”

Source: [Subbiah et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32818466/)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Locoregional Therapy

<a id="topic-2.2.2.1.8-1"></a>

###### Guideline recommendations for ablation, stereotactic radiotherapy, and intra-arterial therapy

> “Local ablation could be considered as an option for patients with iCCA ≤3 cm who have contraindications or are otherwise unfit for surgery [III, B]”
> “SBRT can be considered for patients with iCCA in case of contraindication to surgery for liver-limited disease in the palliative setting [III, C]”
> “Intraarterial therapies, in combination with systemic ChT, can be an option for patients with liver-limited iCCA and discussed by the MDTB according to local availability [III, C]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.2.1.8-2"></a>

###### Hepatic artery infusion pump chemotherapy: pooled analysis of four phase 2 trials

> “Systemic therapy is the standard of care for unresectable intrahepatic cholangiocarcinoma (iCCA), but overall survival (OS) remains poor.”
> “The pooled median OS was 26 months (95% CI 22-30), with 3-year and 5-year OS rates of 28% (95% CI 22-37) and 15% (95% CI 10-23), respectively.”
> “Hepatic artery infusion pump (HAIP) chemotherapy with floxuridine (FUDR) has been shown to prolong survival but is limited to expert centers.”
> “Liver-confined disease was defined as absence of extrahepatic metastatic disease, although locoregional lymph node metastases were allowed in the two most recent trials.”

Source: [Rousian et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42331230/)

<a id="topic-2.2.2.1.8-3"></a>

###### Hepatic artery infusion pump chemotherapy: pump implantation complications and biliary sclerosis

> “Twenty patients (14%) had major postoperative complications following pump implantation requiring reintervention. Three patients (2%) developed ascites, which was treated with percutaneous drainage.”
> “Biliary sclerosis, a long-term complication associated with HAIP chemotherapy with FUDR, necessitated biliary stenting in two patients (1.4%).”

Source: [Rousian et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42331230/)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Best Supportive Care

<a id="topic-2.2.2.1.9-1"></a>

###### Composition of active symptom control in the ABC-06 trial

> “ASC consisted of early identification and treatment of biliary-related complications and cancer-related symptom management; it could include (and was not limited to) the following as per requirements of individual patients: biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy (eg, for painful bone metastases), and transfusion of blood products.”
> “The overall survival rate in the ASC alone group was 35·5% (95% CI 25·2–46·0) at 6 months and 11·4% (5·6–19·5) at 12 months, compared with 50·6% (39·3–60·9) at 6 months and 25·9% (17·0–35·8) at 12 months in the ASC plus FOLFOX group.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

<a id="topic-2.2.2.1.9-2"></a>

###### Quality of life with active symptom control alone versus active symptom control plus FOLFOX

> “FOLFOX did not worsen global, physical, social, or symptom QoL scores, whereas patients receiving ASC recorded declines across several domains.”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.2.1.9-3"></a>

###### Guideline recommendations for biliary drainage and infection

> “In patients with biliary obstruction, biliary drainage and subsequent treatment should be carried out; when endoscopic access is not possible, percutaneous transhepatic drainage is recommended [IV, A]”
> “Sepsis secondary to biliary obstruction is common and should be treated promptly [IV, A]”
> “Patients should be advised of the likely duration of stent patency and of symptoms and signs which are indicative of biliary obstruction or infection [V, A]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Limitations of Current Therapies

<a id="topic-2.2.2.1.10-1"></a>

###### Summary: limitations of current second-line treatment for advanced biliary tract cancer

No systemic regimen is approved by the FDA for second-line advanced biliary tract cancer, and the sponsor of COMPANION-002 states that the therapeutics most commonly used in this setting are not labeled or approved for it, generally produce an objective response rate of about 5% or less, and are associated with a median overall survival of approximately six months. First-line chemoimmunotherapy improves survival only modestly: the hazard ratio for overall survival was 0.80 with durvalumab added to gemcitabine and cisplatin and 0·83 with pembrolizumab added to gemcitabine and cisplatin, with median overall survival of 12·7 versus 10·9 months in KEYNOTE-966, and a 2026 review states that median overall survival remains around 1 year.

The second-line evidence base rests on one positive phase 3 trial. In ABC-06, 162 participants were randomized, median overall survival was 6·2 months with active symptom control plus FOLFOX versus 5·3 months with active symptom control alone, and an objective response occurred in 4 of 81 participants (5%). The Pan-Asian adaptation of the ESMO guideline downgraded the level of evidence from I to II and the grade of recommendation from A to B, noting the limited survival benefit and the absence of Asian participants. Randomized evidence for liposomal irinotecan is inconsistent: NIFTY reported a median blinded independent central review progression-free survival of 7·1 versus 1·4 months, whereas NALIRICC reported 2·6 versus 2·3 months with a hazard ratio of 0·87 and no overall survival benefit, and a pooled analysis of the two trials (278 participants) found a median progression-free survival of 3.6 versus 1.8 months. A meta-analysis of 17 randomized trials in 4,584 participants concluded that a breakthrough in advanced biliary tract cancer treatment remains elusive.

Biomarker-directed options apply to a minority. Guideline-recommended targeted therapies address FGFR2 fusions or rearrangements, IDH1 mutations, HER2 overexpression or amplification, BRAF V600E mutations, NTRK fusions, RET fusions, and mismatch repair deficient or tumor mutational burden-high disease, but the COMPANION-002 investigators state that only a minority of biliary tract cancers harbor these alterations and report frequencies of 4% to 5% for BRAF V600E, less than 1% for NTRK fusions, less than 1% for RET fusions, and 1% to 2% for microsatellite instability, while the sponsor states that approximately 85% of participants have no actionable mutation with an approved targeted therapy. Where targeted agents do apply, benefit is time-limited: ivosidenib improved median progression-free survival from 1·4 to 2·7 months and did not reach statistical significance for overall survival in the intention-to-treat analysis, FGFR inhibition is followed by acquired FGFR2 resistance mutations, and a next-generation FGFR inhibitor produced an objective response rate of 6·3% in tumors with primary FGFR inhibitor resistance. No standardized criteria exist for assessing HER2 status in biliary tract cancer and no specific test can be recommended.

Toxicity and delivery constrain use. Grade 3 to 5 adverse events occurred in 56 of 81 participants (69%) receiving active symptom control plus FOLFOX, including three chemotherapy-related deaths; the addition of a third cytotoxic agent to gemcitabine and cisplatin increases treatment-related toxicity and did not improve overall survival in SWOG S1815; trastuzumab deruxtecan caused adjudicated drug-related interstitial lung disease in 10.5% of participants with three deaths; and pemigatinib caused hyperphosphatemia in 58.5% of participants. Locoregional options are confined to liver-limited or unresectable non-metastatic disease rather than the second-line metastatic setting, and intra-arterial therapy availability varies by region.

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm); [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm); [Oh et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319896/); [Kelley et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37075781/); [Yoon and Yoo (2026)](https://pubmed.ncbi.nlm.nih.gov/41429598/); [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/); [Yoo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34656226/); [Vogel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38870977/); [Yoo et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40147791/); [Li et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11840543/); [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/); [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/); [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523268/); [Javle et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41349554/); [Shroff et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11798714/); [Meric-Bernstam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10730032/); [Vogel et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11190465/)

<a id="topic-2.2.2.1.10-2"></a>

###### No approved second-line therapy for the majority without an actionable alteration

> “For the vast majority of patients with BTC whose tumors do not harbor an actionable mutation with an approved targeted therapy, there is currently no FDA-approved treatment in the second line setting.”
> “The therapeutics most commonly used in this setting, which are not labeled or approved by the FDA for the treatment of patients with BTC, generally have an ORR of ~5% or less and patients face a median OS of approximately six months.”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

> “A treatment option is urgently needed for patients with tumors without an obvious actionable alteration.”
> “While several targeted therapies have gained approval for addressing gene alterations that are relevant in BTC, only a minority of BTCs harbor these alterations.”
> “In a randomized study in the second-line setting, the three drug combination regimen FOLFOX improved median overall survival by 0.9 months compared with best supportive care”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.2.2.1.10-3"></a>

###### Guideline statement on the unmet need in patients without a targetable alteration

> “Nearly 40% of patients with BTC harbour genetic alterations which are potential targets for precision medicine.”
> “There remains, therefore, an urgent need to develop new therapies, particularly for patients who lack a targetable genomic alteration.”

Source: [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/)

<a id="topic-2.2.2.1.10-4"></a>

###### Downgraded strength of the second-line chemotherapy recommendation

> “Furthermore, FOLFOX treatment showed a limited survival benefit compared with active symptom control (6.2 months for FOLFOX versus 5.3 months for active symptom control).”
> “Moreover, because the ABC-06 trial is the only positive phase III trial for the second-line treatment of BTC, the LoE was also downgraded from ‘I’ to ‘II’.”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.2.1.10-5"></a>

###### Proposed explanations for the divergent NIFTY and NALIRICC results

> “Treatment discontinuation due to toxicity, without disease progression, was more common in the NALIRICC trial compared to the NIFTY trial.”
> “As the efficacy of cytotoxic chemotherapy is often limited by early discontinuation, this might be one of the potential reasons why the ORR improvement did not translate into better survival outcomes.”
> “This study is limited by its unplanned nature, which may introduce biases, resulting in a lower level of evidence compared to a single randomized trial.”

Source: [Yoo et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40147791/)

<a id="topic-2.2.2.1.10-6"></a>

###### Internal validity and generalizability limitations of the NIFTY trial

> “As this result implies that the HRs for progression-free survival might not be representative for the entire study period, further validation should be done in a large, phase 3 trial.”
> “Because this trial was done in a single country and all patients were of east Asian ethnicity, its findings might have limited generalisability.”

Source: [Yoo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34656226/)

<a id="topic-2.2.2.1.10-7"></a>

###### Survival remains approximately one year despite recent advances

> “Although recent advances have improved clinical outcomes in patients with advanced BTC, median overall survival remains around 1 year, underscoring the need for further therapeutic innovation.”
> “Several targeted agents have demonstrated clinically meaningful efficacy in phase 2-3 trials and are recommended as subsequent-line therapy for biomarker-selected disease, including FGFR2 gene rearrangements, IDH1 mutations, and HER2 amplification.”

Source: [Yoon and Yoo (2026)](https://pubmed.ncbi.nlm.nih.gov/41429598/)

> “Despite incremental advancements, a breakthrough in advanced BTC treatment remains elusive.”

Source: [Li et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11840543/)

<a id="topic-2.2.2.1.10-8"></a>

###### No objective response rate benefit from adding pembrolizumab to first-line chemotherapy

> “The efficacy boundary for a statistically significant objective response rate benefit for the pembrolizumab group was not met (treatment difference 0·2 percentage points [95% CI –5·2 to 5·6]; p=0·47).”
> “There was also no difference between treatment groups in objective response rate.”

Source: [Kelley et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37075781/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: anticipated position of tovecimig

Tovecimig is investigational and has no marketing authorization. Its anticipated population is the population enrolled in COMPANION-002: adults with unresectable advanced, metastatic, or recurrent biliary tract cancer, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma, who have radiologically documented progression after one prior gemcitabine and platinum containing regimen and who have an Eastern Cooperative Oncology Group performance status of 0 or 1. The trial randomized 168 participants 2:1 to tovecimig plus paclitaxel or paclitaxel alone and allowed crossover after centrally confirmed progression.

No positive biomarker is required for selection. Molecular testing is nonetheless relevant to eligibility, because the trial excluded participants who were eligible for a molecularly targeted therapy on a labelled regimen after first-line chemotherapy. The sponsor frames the target population as the approximately 85% of participants whose tumors do not harbor an actionable mutation with an approved targeted therapy, for whom there is no FDA-approved second-line treatment. In current guidelines that population receives FOLFOX, with irinotecan-based or liposomal irinotecan-based regimens as alternatives, so tovecimig plus paclitaxel would enter second-line treatment as an alternative to fluoropyrimidine-based chemotherapy rather than displacing a biomarker-directed option.

The regimen is entirely parenteral and requires an infusion setting. Paclitaxel 80 mg/m2 is given intravenously on days 1, 8, and 15 of each 28-day cycle, and tovecimig 10 mg/kg is given intravenously on days 1 and 15 of each 28-day cycle, so participants attend three infusion visits per 28-day cycle. Regulatory status as of November 2026 is pre-submission: the sponsor reported in August 2026 that it expected FDA feedback in the third quarter of 2026 and planned to include the COMPANION-002 data in a Biologics License Application later in 2026. In September 2026 the FDA recommended a trial demonstrating a survival benefit before a submission, and in November 2026 the sponsor stated that it continues to prepare a submission; the full dataset was published in the Journal of Clinical Oncology and presented at the October 2026 ESMO Congress.

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943); [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/); [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/); [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm); [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm); [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm); [Compass Therapeutics regulatory update announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326006162/exh_991.htm); [Compass Therapeutics third quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326007256/exh_991.htm); [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.2.2-2"></a>

###### Unmet need the sponsor identifies in the second-line setting

> “For the approximately 85% of patients with BTC whose tumors do not harbor an actionable mutation with an approved targeted therapy, there is currently no FDA-approved treatment in the second line setting.”
> “We believe these findings highlight the potential of tovecimig to provide a much-needed treatment option for the majority of patients with BTC who have limited alternatives after first-line therapy.”
> “Patients currently have very limited treatment options, with the vast majority in the second-line setting having no approved therapeutic alternative whatsoever.”

Source: [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm)

> “These results are a significant step forward and I anticipate that, if approved, it will meaningfully change the way physicians care for these patients.”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-2.2.2.2-3"></a>

###### Eligibility without positive biomarker selection

> “Patients who are eligible to be treated with a molecularly targeted therapy on a labelled regimen after receiving first-line chemotherapy.”
> “Stratification factors include stage (locally advanced vs metastatic), anatomic subtype of the primary tumor (intrahepatic cholangiocarcinoma vs other) and ECOG performance status (0 or 1).”
> “Patients are randomized to a 2:1 ratio, and crossover is allowed to the experimental arm at the time of progression in the control arm for patients that continue to meet eligibility criteria.”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.2.2.2-4"></a>

###### Care setting: intravenous administration in the COMPANION-002 regimen

| Field | Registry record |
| --- | --- |
| Official title | “A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen” |
| Intervention description, CTX-009 | “IV infusion on day 1 and 14 of every 28 day cycle” |
| Intervention description, paclitaxel | “IV infusion on day 1, 8, and 15 of every 28 day cycle” |
| Comparator arm description | “Patients randomized to receive paclitaxel only have the option to crossover to the CTX-009 plus paclitaxel arm after documented disease progression per RECIST v1.1.” |
| Overall status | “Active, not recruiting” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

> “The study enrolled 168 adult patients, randomized in a 2:1 ratio to receive tovecimig plus paclitaxel (n=111) or paclitaxel alone (n=57). All patients were dosed with 80 mg/m2 of paclitaxel on days 1, 8 and 15 of every 28-day cycle. Patients in the tovecimig arm were also dosed with 10 mg/kg of tovecimig on days 1 and 15 of each 28-day cycle.”
> “Patients in the paclitaxel-only arm who progressed could cross over to the tovecimig plus paclitaxel arm after centrally confirmed progression if they also still met the enrollment criteria for the study.”

Source: [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm)

<a id="topic-2.2.2.2-5"></a>

###### Regulatory position ahead of anticipated use

> “In the coming months, Compass intends to meet with the U.S. Food and Drug Administration (FDA) to discuss these data in advance of a planned BLA submission.”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

> “The company expects to receive feedback from the FDA on these data in Q3 2026.”
> “In April 2026, the Company announced positive data from its Phase 2/3 study of tovecimig, which it plans to include in a BLA submission later this year.”
> “Tovecimig data from this study has also been selected for an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in October.”

Source: [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm)

<a id="topic-2.2.2.2-6"></a>

###### Regulatory position after publication of the complete dataset

> “We continue to prepare the BLA submission for tovecimig and are working to engage the FDA to bring this important therapy to patients with BTC as quickly as possible. The full COMPANION-002 results, now published in the Journal of Clinical Oncology and presented at ESMO, highlight the strength of the supportive data for tovecimig.”

Source: [Compass Therapeutics third quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326007256/exh_991.htm)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Summary: reported and anticipated modifiers of treatment effect

COMPANION-002 prespecified three stratification factors that define the subgroups in which effect modification would be examined: stage (locally advanced versus metastatic), anatomic subtype of the primary tumor (intrahepatic cholangiocarcinoma versus other), and Eastern Cooperative Oncology Group performance status (0 or 1). The peer-reviewed publication of the complete dataset reports one of these subgroups, intrahepatic cholangiocarcinoma, with an objective response rate of 15.3% versus 0% and median progression-free survival of 5.1 versus 3.0 months (hazard ratio 0.32), and states that the study was not powered to evaluate efficacy within individual anatomical or molecular subgroups. No subgroup analysis by stage, performance status, prior therapy, or geography has been reported.

The heterogeneity that the sponsor has reported concerns crossover rather than baseline characteristics. Of 57 participants randomized to paclitaxel alone, 31 (54%) crossed over after centrally confirmed progression. Within that control arm, participants who crossed over had a median overall survival of 12.8 months versus 6.1 months for those who did not (hazard ratio 0.54, p=0.04), despite having progressed faster on initial paclitaxel monotherapy (median progression-free survival 1.9 versus 3.6 months, hazard ratio 2.31, p=0.007). In the same 31 participants, median progression-free survival after crossover was 3.5 months compared with 1.9 months before crossover (hazard ratio 0.36, p=0.0016). These are post hoc or within-participant comparisons in a non-randomized subset, and the sponsor states that the rank-preserving structural failure time adjustment for crossover rested on assumptions that were not met and is largely uninterpretable.

No predictive biomarker for DLL4 or VEGF-A blockade has been established in biliary tract cancer. The COMPANION-002 investigators describe DLL4 as highly expressed in biliary tract cancer with up-regulation associated with poor survival, and VEGF-A overexpression as correlating with stage, presence of metastases, and prognosis, but these are prognostic observations and the trial did not select participants by DLL4 or VEGF-A expression. By contrast, the comparator landscape is strongly biomarker-defined: response rates differ from 37.0% with pemigatinib and 42% with futibatinib in FGFR2 fusion-positive disease, to 41·3% with zanidatamab and 46.7% with tucatinib plus trastuzumab in HER2-positive disease, to 61.3% with trastuzumab deruxtecan in centrally confirmed HER2 immunohistochemistry 3+ tumors, to 51% with dabrafenib plus trametinib in BRAF V600E-mutated disease, against 5% with FOLFOX in unselected second-line participants.

Modifiers observed in the comparator trials are mainly clinical rather than molecular. In ABC-06 the survival benefit of FOLFOX was independent of platinum sensitivity, subgroups with suspected poorer prognosis appeared to benefit most, and the benefit appeared weaker in the extrahepatic cholangiocarcinoma subgroup, though the investigators state that the subgroup analyses were insufficiently powered. In SWOG S1815, the addition of nab-paclitaxel improved progression-free survival more in gallbladder carcinoma than in intrahepatic or extrahepatic cholangiocarcinoma (interaction P = .01) without a corresponding overall survival interaction. In the ABC-06 biomarker analysis, median overall survival fell from 8.9 months when no tumor marker was elevated to 3.2 months when carbohydrate antigen 19-9, carcinoembryonic antigen, and cancer antigen 125 were all elevated.

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/); [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/); [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm); [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm); [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/); [Harding et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37276871/); [Nakamura et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10730072/); [Meric-Bernstam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10730032/); [Subbiah et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32818466/); [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Shroff et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11798714/); [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.2.3-2"></a>

###### Prespecified stratification factors in COMPANION-002

> “Stratification factors include stage (locally advanced vs metastatic), anatomic subtype of the primary tumor (intrahepatic cholangiocarcinoma vs other) and ECOG performance status (0 or 1).”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.2.2.3-3"></a>

###### Crossover subsets of the paclitaxel control arm

> “In an analysis of OS in all patients randomized to the paclitaxel control arm (n=57), crossover patients who subsequently received tovecimig demonstrated a statistically significant improvement in median OS of 12.8 months compared to 6.1 months for non-crossover patients who received only paclitaxel (HR=0.54, p=0.04).”
> “Another analysis of these same patients randomized to the paclitaxel control arm (n=57) demonstrated that the crossover patients initially progressed faster on paclitaxel monotherapy compared to the non-crossover patients, with a median PFS of 1.9 months versus 3.6 months (HR=2.31, p=0.007).”
> “In this subset, tovecimig demonstrated a statistically significant improvement with median PFS2 of 3.5 months after treatment with tovecimig compared to median PFS1 of 1.9 months for paclitaxel (HR=0.36, p=0.0016).”
> “Though the RPSFT analysis is intended to adjust for crossover, its validity depends on certain assumptions that were not met in this study and thus its results here are largely uninterpretable.”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-2.2.2.3-4"></a>

###### DLL4 and VEGF-A expression as prognostic rather than selection markers

> “DLL4 is highly expressed in BTC and up-regulation of DLL4 expression is associated with poor survival in patients with BTC”
> “VEGF-A overexpression has been reported in BTC, correlating with stage, the presence of metastases and prognosis of the disease”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.2.2.3-5"></a>

###### Statistical power for anatomic subtype effects in the NIFTY trial

> “Although our trial was adequately powered for the primary endpoint and had a sample size (n=174) larger than that of the phase 3 ABC-06 trial (n=162), it might be insufficient to fully show the impact of liposomal irinotecan in each subtype of biliary tract cancer.”

Source: [Yoo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34656226/)

<a id="topic-2.2.2.3-6"></a>

###### Subgroup and ethnicity findings in the pooled NIFTY and NALIRICC analysis

> “In the prespecified subgroup analysis, nal-IRI plus 5-FU/LV showed benefit in most subgroups for PFS and OS, with the exception of patients with ECOG performance status 0 and elevated baseline C-reactive protein levels”
> “In addition, there was no significant interaction between the two trials for the efficacy of additional nal-IRI (p = 0.12 for PFS and p = 0.09 for OS).”
> “Ethnic differences were observed in the AE patterns: gastrointestinal toxicities, such as nausea, vomiting, and diarrhea, were more common and severe in German patients, whereas neutropenia was more frequent in Korean patients.”

Source: [Yoo et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40147791/)

<a id="topic-2.2.2.3-7"></a>

###### Subgroup findings in the second-line chemotherapy comparator

> “The ABC-06 study showed how the overall survival and progression-free survival benefit was independent of whether patients were classed as being platinum sensitive or platinum refractory or resistant. In fact, subgroups with suspected poorer prognosis seemed to benefit most from FOLFOX.”
> “Our subgroup analysis also showed a weaker overall survival benefit from treatment with FOLFOX in the extrahepatic cholangiocarcinoma subgroup; however, this observation should be viewed with caution owing to insufficient statistical power.”
> “The insufficient power for subgroup analyses, which challenges some interpretations, is an acknowledged limitation, especially in such a heterogeneous disease.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

<a id="topic-2.2.2.3-8"></a>

###### Anatomic subtype as an effect modifier for taxane-containing chemotherapy

> “Moreover, GAP versus GC showed greater improvement in PFS among participants with GBC than those with ICC or ECC (interaction P = .01), but not OS (interaction P = .28).”

Source: [Shroff et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11798714/)

<a id="topic-2.2.2.3-9"></a>

###### Tumor markers as prognostic stratifiers in second-line treatment

> “In addition, median OS decreased from 8.9 months (no markers elevated) to 3.2 months (all three elevated).”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.2.3-10"></a>

###### Absence of a predictive biomarker for first-line immune checkpoint inhibitor choice

> “At present, there are no discernible clinical, biochemical or molecular biomarkers, nor any notable differences in efficacy or toxicity, favouring one immune checkpoint inhibitor over the other.”

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)

<a id="topic-2.2.2.3-11"></a>

###### Molecular covariates of response to futibatinib in FGFR2-altered disease

> “Analysis of the molecular profile of the tumors in the 103 patients in the efficacy population indicated that responses did not correlate with FGFR2 fusion-partner status or co-occurring alterations in tumor-suppressor genes or oncogenes (Fig. 2).”
> “Numerical differences were noted with respect to median progression-free survival between patients with and those without CDKN2A (4.9 months and 9.7 months, respectively) and those with and those without CDKN2B alterations (4.8 months and 11.0 months).”

Source: [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/)

<a id="topic-2.2.2.3-12"></a>

###### HER2 immunohistochemistry score as a modifier of response to zanidatamab

> “Although the trial was not designed to distinguish treatment effect by HER2 status, higher response rates were observed in patients with biliary tract cancer with HER2 IHC 3+ than in those with HER2 IHC 2+.”
> “For cohort 2, median progression-free survival was 1·9 months (95% CI 1·2–not estimable) and median overall survival was 5·5 months (95% CI 1·2–10·1).”

Source: [Harding et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37276871/)

<a id="topic-2.2.2.3-13"></a>

###### Absence of molecular correlates of response to dabrafenib plus trametinib

> “The findings of our exploratory DNA sequencing analysis did not highlight any specific gene alterations that could be attributed to responders or non-responders, although the small sample size (n=16) did not allow for formal statistical comparisons.”

Source: [Subbiah et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32818466/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Summary: monitoring and supportive care relevant to tovecimig plus paclitaxel

Three strands of care management apply. First, molecular profiling determines whether a participant belongs to the biomarker-directed pathway or to the chemotherapy pathway that tovecimig targets; guidelines recommend profiling when first-line systemic treatment is initiated, and COMPANION-002 excluded participants eligible for a labelled targeted regimen. Second, biliary tract cancer requires ongoing biliary and infection management independent of systemic therapy: guidelines recommend biliary drainage with percutaneous transhepatic drainage when endoscopic access is not possible, prompt treatment of sepsis secondary to biliary obstruction, patient education on stent patency and on the signs of obstruction or infection, and follow-up every 8 to 12 weeks with computed tomography or magnetic resonance imaging supplemented by carbohydrate antigen 19-9 or carcinoembryonic antigen when secreted. COMPANION-002 required adequate biliary excretion at entry and excluded participants with percutaneous transhepatic biliary drains.

Third, the adverse event profile of tovecimig plus paclitaxel defines the monitoring program. The most common treatment-emergent adverse events in the combination arm were hypertension (69%) and fatigue (67%), and the most common related grade 3 or higher events were hypertension (44%) and neutropenia (36%), which indicates a need for blood pressure measurement at every visit with antihypertensive management, and for complete blood counts before each weekly paclitaxel dose. The angiogenesis-directed mechanism is reflected in the trial's entry requirements and exclusions, which covered urine protein by dipstick with 24-hour confirmation, uncontrolled hypertension, hemorrhage-related and gastroenterological disease, and current or recent therapeutic anticoagulation or antiplatelet use, so proteinuria, bleeding risk, and concomitant anticoagulation require assessment before and during treatment. In the earlier phase 2 study of the same combination the most frequent grade 3 or higher events were neutropenia (50.0%), hypertension (16.7%), anemia (12.5%), and thrombocytopenia (8.3%).

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/); [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/); [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/); [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm); [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-2.2.2.4-2"></a>

###### Molecular profiling to assign the treatment pathway

> “Molecular profiling is recommended when first-line systemic treatment is initiated in patients with locally advanced, advanced or metastatic disease, particularly in those at high risk of progression or recurrence [I, A].”

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)

<a id="topic-2.2.2.4-3"></a>

###### Follow-up interval and tumor marker monitoring during systemic therapy

> “During systemic and locoregional therapy for advanced disease, follow-up should be conducted at a frequency of 8-12 weeks. In addition to imaging with CT or MRI, CA 19-9 or CEA levels may be used to monitor the course of the disease if one or both are known to be secreted [IV, A]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.2.4-4"></a>

###### Biliary drainage, infection management, and patient education

> “In patients with biliary obstruction, biliary drainage and subsequent treatment should be carried out; when endoscopic access is not possible, percutaneous transhepatic drainage is recommended [IV, A]”
> “Sepsis secondary to biliary obstruction is common and should be treated promptly [IV, A]”
> “Patients should be advised of the likely duration of stent patency and of symptoms and signs which are indicative of biliary obstruction or infection [V, A]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.2.4-5"></a>

###### Adverse events requiring monitoring with tovecimig plus paclitaxel

> “Tovecimig was generally well tolerated and the safety profile was consistent with previously reported data from prior studies, with no new safety signals. The most commonly reported treatment emergent adverse events in the tovecimig combination arm were hypertension (69%) and fatigue (67%). The most common related treatment-emergent adverse events of Grade 3 or higher included hypertension (44%) and neutropenia (36%).”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

> “The most frequent TEAEs of grade 3 or higher were neutropenia (50.0%), hypertension (16.7%), anemia (12.5%) and thrombocytopenia (8.3%)”

Source: [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)

<a id="topic-2.2.2.4-6"></a>

###### Baseline assessments and exclusions relevant to angiogenesis blockade

| Field | Registry record |
| --- | --- |
| Inclusion criterion, biliary excretion | “No evidence of ongoing infection and adequate biliary excretion or patients whose adequate biliary excretion can be confirmed with the following procedures:” |
| Inclusion criterion, proteinuria | “Urine protein ≤ 1+ by Dipstick” |
| Exclusion criterion, biliary drains | “Patients with percutaneous transhepatic biliary drains (PTBD)” |
| Exclusion criterion, targeted therapy eligibility | “Patients who are eligible to be treated with a molecularly targeted therapy on a labelled regimen after receiving first-line chemotherapy.” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary: expected outcomes and the benchmarks they are measured against

COMPANION-002 defines the outcomes tovecimig plus paclitaxel is expected to achieve. The primary endpoint is the proportion of participants whose best overall response is complete or partial response by RECIST version 1.1, and the secondary endpoints are progression-free survival, duration of response, overall survival, disease control rate, and treatment-emergent adverse events.

On the primary endpoint, the final analysis reported an objective response rate of 18.0% (20 of 111 participants) with tovecimig plus paclitaxel versus 5.3% with paclitaxel alone (p=0.0228), revised from the 17.1% versus 5.3% (p=0.031) reported at the April 2025 top-line analysis after one participant was adjudicated by blinded independent central review as a partial response. Progressive disease as best overall response occurred in 16.2% of the combination arm versus 42.1% of the control arm. On the key secondary endpoint, median progression-free survival by blinded independent central review was 4.7 months versus 2.6 months (hazard ratio 0.44, p<0.0001). Overall survival did not reach statistical significance: median overall survival was 8.9 months with the combination and 9.4 months in the control arm (hazard ratio 1.05, p=0.78), which the sponsor attributes to 31 of 57 control participants (54%) crossing over, with the result that 142 of 168 participants (85%) received tovecimig and the pooled median overall survival across the study was 8.9 months.

These values are to be read against the benchmarks the sponsor and the guideline evidence describe for second-line treatment: an objective response rate of approximately 5% or less and a median overall survival of approximately six months with the regimens most commonly used off-label; a median overall survival of 6·2 months with FOLFOX versus 5·3 months with active symptom control and an objective response in 4 of 81 participants (5%) in ABC-06; and a median blinded independent central review progression-free survival of 7·1 months with liposomal irinotecan plus fluorouracil and leucovorin in NIFTY against 2·6 months in NALIRICC. The peer-reviewed publication of the complete dataset reports a median duration of response of 21.4 weeks and a disease control rate of 62.2% versus 36.8% with tovecimig plus paclitaxel and paclitaxel alone. No health-related quality of life outcome for tovecimig has been reported; the publication states that quality-of-life analyses will be reported separately.

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943); [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/); [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm); [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm); [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm); [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Yoo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34656226/); [Vogel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38870977/)

<a id="topic-2.2.2.7-2"></a>

###### Endpoints COMPANION-002 is designed to measure

| Field | Registry record |
| --- | --- |
| Primary outcome measure | “Best Overall Response” |
| Primary outcome description | “Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR) as assessed by RECIST 1.1” |
| Secondary outcome measure | “Progression Free Survival” |
| Secondary outcome measure | “Duration of Response” |
| Secondary outcome measure | “Overall Survival” |
| Secondary outcome measure | “Disease Control Rate” |

Source: [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)

<a id="topic-2.2.2.7-3"></a>

###### Response rate achieved in the final analysis

> “In the final data analysis, the overall response rate (ORR), the primary endpoint in the study, improved to 18.0% (20/111 patients) in the tovecimig combination arm from a previously reported 17.1%.”
> “With this change, the p-value improved to 0.0228 compared to paclitaxel alone (ORR of 5.3% in the paclitaxel arm).”

Source: [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm)

> “The study also showed differences between treatment arms for other efficacy measures, including progressive disease (PD) rates of 16.2% in patients on tovecimig in combination with paclitaxel versus 42.1% in patients on paclitaxel alone.”

Source: [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm)

<a id="topic-2.2.2.7-4"></a>

###### Progression-free survival and overall survival achieved

> “Tovecimig in combination with paclitaxel demonstrated a statistically significant improvement in median PFS of 4.7 months compared to 2.6 months for paclitaxel alone (HR=0.44, p<0.0001). Progression was confirmed in each case by BICR.”
> “In the ITT OS analysis, tovecimig in combination with paclitaxel had a median OS of 8.9 months compared to 9.4 months for the control arm, which included 26 patients (46%) who received paclitaxel alone and 31 patients (54%) who crossed over to receive tovecimig in combination with paclitaxel (HR=1.05, p=0.78).”
> “Including crossover, 85% of patients in the study received tovecimig in combination with paclitaxel and the pooled median OS for all patients in the study was 8.9 months, which is also substantially longer than chemotherapy benchmarks of approximately 6 months.”

Source: [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)

<a id="topic-2.2.2.7-5"></a>

###### Comparator benchmarks for response and survival in the second-line setting

> “The combinations of therapeutics used in this setting, which are not labeled for this indication, generally have an ORR of ~5% or less and patients face a median overall survival of approximately six months.”

Source: [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm)

> “Overall survival was significantly longer in the ASC plus FOLFOX group than in the ASC alone group, with a median overall survival of 6·2 months (95% CI 5·4–7·6) in the ASC plus FOLFOX group versus 5·3 months (4·1–5·8) in the ASC alone group (adjusted hazard ratio 0·69 [95% CI 0·50–0·97]; p=0·031).”
> “Objective response was observed in four (5%) of 81 patients in the ASC plus FOLFOX group: one (1%) patient had a complete response and three (4%) patients had a partial response.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

> “second-line FOLFOX resulted in a median progression-free survival of 4·0 months (95% CI 3·2–5·0), a median overall survival of 6·2 months (95% CI 5·4–7·6), and an objective response rate of 5%.”

Source: [Yoo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34656226/)

<a id="topic-2.2.2.7-6"></a>

###### Quality of life during second-line liposomal irinotecan

> “Our quality of life analysis showed that the addition of liposomal irinotecan did not impair global health status.”

Source: [Yoo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34656226/)

## Related pages
- [Tovecimig (CTX-009): Second-line advanced biliary tract cancer](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Terms and abbreviations](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/terms-and-abbreviations.md)
- [Tovecimig (CTX-009): Second-line advanced biliary tract cancer](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/executive-summary.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Clinical evidence](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/clinical-evidence.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Economic information and modeling report](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/economics.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: References](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/references) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/references.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: formulary monograph](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/monograph) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/monograph.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: drug evaluation](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/monograph/oregon) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/monograph/oregon.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: prevalence by geography](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/prevalence) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/prevalence.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/cost-effectiveness-analyses.md)
